Core Indicators for Monitoring the Ending the HIV Epidemic Initiative

Print
Related Pages
HIV Surveillance Data Tables

Core Indicators for Monitoring the Ending the HIV Epidemic Initiative:
National HIV Surveillance System Data Reported through December 2022; and Preexposure Prophylaxis (PrEP) Data Reported through September 2022

This issue of HIV Surveillance Data Tables is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through December 2022 and preexposure prophylaxis (PrEP) data reported through September 2022.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative: National HIV Surveillance System data reported through December 2022; and preexposure prophylaxis (PrEP) data reported through September 2022. HIV Surveillance Data Tables 2022;3(4). https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/. Published May 2023. Accessed [date].

Technical Notes

The Ending the HIV Epidemic in the U.S. (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The included tables provide national-, state-, and county-level (EHE Phase I jurisdictions only; see Table 7) data for the 6 core indicators of the EHE initiative, which are the following:

  • New HIV infections: the estimated number of new HIV infections in a calendar year.
  • Knowledge of HIV status: the estimated percentage of persons with HIV who have received a diagnosis.
  • Diagnoses of HIV infection: the number of HIV infections confirmed by laboratory or clinical evidence in a calendar year.
  • Linkage to HIV medical care: the percentage of persons who have received a diagnosis of HIV infection in a calendar year and were linked to HIV medical care within 1 month.
  • HIV viral suppression: the percentage of persons living with diagnosed HIV who have a suppressed viral load at the most recent test in a calendar year.
  • Preexposure prophylaxis (PrEP) coverage: the percentage of the number of persons prescribed PrEP in a calendar year relative to the estimated number of persons with indications for PrEP in a calendar year.

The Centers for Disease Control and Prevention (CDC) routinely releases HIV Surveillance Data Tables on the core indicators for EHE to allow for more timely monitoring of progress.

Surveillance of HIV Infection

Data presented were reported (after the removal of personally identifiable information) to the CDC through December 31, 2022. Please use caution when interpreting the following:

  • Data for the year 2020. Should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. [2–6].
  • Data for the year 2022. Data provided using a National HIV Surveillance System (NHSS) dataset produced prior to reaching a 12-month reporting lag are considered preliminary.
  • HIV incidence and prevalence estimates. Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the CD4+ T-lymphocyte (CD4)-based depletion model [7] to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. The original CD4-based model assumes stable testing and diagnosis trends during the period assessed. However, the COVID-19 pandemic caused both HIV testing [5, 6] and HIV diagnoses [8, 9] to deviate from recent trends. The monthly distribution of diagnoses occurring during 2020 and 2021 were adjusted to account for excess delay. See the Technical Notes of Estimated HIV incidence and prevalence in the United States, 2017–2021 at https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html for additional information.
  • Data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection.
  • Deaths and prevalence-based data (HIV viral suppression) due to known delays in reporting of deaths to CDC.
  • Numbers less than 12 and trends based on these numbers.

Tabulation and Presentation of Data

New HIV Infections (HIV Incidence)

New HIV infections among persons aged ≥ 13 years are estimated using the first CD4 test result after HIV diagnosis and a CD4-depletion model indicating disease progression or duration after infection (Tables 1a–c).

More information on estimating new HIV infections can be found at in the report Estimated HIV incidence and prevalence in the United States, 2017–2021 at https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

Knowledge of HIV Status

The Knowledge of HIV Status indicator is measured as the percentage of persons aged ≥ 13 years with diagnosed HIV infection (Tables 2a–c). For this measure, the numerator (data reported to CDC) is the number of persons aged ≥ 13 years living with diagnosed HIV infection at the end of the year. The denominator, total HIV prevalence, is the estimated number of persons aged ≥13 years living with HIV infection (diagnosed or undiagnosed) at the end of the year. Knowledge of status and prevalence data for the year 2021 are preliminary and based on death data reported to CDC as of December 2022. The following areas had incomplete reporting of deaths for the year 2021, and prevalence estimates should be interpreted with caution: Mississippi. Estimates for areas without laws requiring reporting of laboratory data, or with incomplete reporting of laboratory data to CDC, should also be interpreted with caution. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia County), and Puerto Rico.

More information on calculating HIV prevalence and percentage of persons with diagnosed HIV infection can be found in the report Estimated HIV incidence and prevalence in the United States, 2017–2021 at https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥ 13 years with HIV diagnosed during 2017–2022 (Tables 3a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2016–2020 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting diagnoses of HIV infection can be found in the HIV Surveillance Report, 2021 at https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years whose infection was diagnosed during January 2021 through September 2022 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 4a–c). The numerator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during January 2021 through September 2022 and who had ≥ 1 CD4 or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years whose HIV infection was diagnosed during January 2021 through September 2022. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2021 through September 2022 and reported to NHSS through December 2022. Data are not provided for states and associated areas that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia County, and Puerto Rico.

More information on calculating linkage to care can be found at in the report Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021 at https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

HIV Viral Suppression

Viral suppression at most recent test during 2021 is measured for persons aged ≥ 13 years who resided, as of their most recent known address during 2021, in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC and who were alive at the end of 2021 (Tables 5a–c). The numerator is the number of persons aged ≥ 13 years with HIV infection diagnosed by the end of 2020 and who had a VL of < 200 copies/mL at the most recent test in 2021. The denominator is the number of persons aged ≥ 13 years with HIV diagnosed by the end of 2020 and who were alive at the end of 2021. Data used to calculate prevalence are based on deaths reported to CDC as of December 2022. The following areas had incomplete reporting of deaths for the year 2021, and viral suppression data should be interpreted with caution: Mississippi. Data are not provided for states and associated areas that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia County), and Puerto Rico.

More information on calculating viral suppression can be found in the report Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021 at https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged ≥ 16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥ 16 years who had indications for PrEP during the specified year (Tables 6a–c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥ 16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 93% of all prescriptions from retail pharmacies and 77% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [10–12]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Long-acting injectable cabotegravir (CAB-LA) was approved by the FDA as an additional prevention option for PrEP in December 2021. TAF/FTC and injectable cabotegravir were included in the algorithm after their approval to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for < 40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic Designations

In the IQVIA database, a person’s location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau’s American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [13], and (b) the U.S Department of Housing and Urban Development’s ZIP Code Crosswalk Files [14]. Because of reliability concerns, subnational estimates of < 40 are not included.

Persons with PrEP indications

U.S. Census Bureau files and their ACS were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [15, 16]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [17].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [15]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years January 2017–September 2022 by using the IQVIA data reported through September 2022. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of HIV Surveillance Data Tables, 2018 denominators were used for 2019, 2020, 2021, and 2022 PrEP coverage data; consequently, 2019 through September 2022 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions [18].

More information on calculating PrEP coverage can be found in the report Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021 at https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html

References

  1. HHS. What is Ending the HIV Epidemic in the U.S.? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Updated July 2, 2022. Accessed March 13, 2023.
  2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. MMWR 2020;69(18):551–556. doi:http://dx.doi.org/10.15585/mmwr.mm6918e2
  3. Delaney KP, Jayanthi P, Emerson B, et al. Impact of COVID-19 on commercial laboratory testing for HIV in the United States. 2021 CROI, March 6–10, 2021. Abstract 739.
  4. Moitra E, Tao J, Olsen J, et al. Impact of the COVID-19 pandemic on HIV testing rates across four geographically diverse urban centres in the United States: an observational study. Lancet Reg Health Am 2022;7:100159. doi:10.1016/j.lana.2021.100159
  5. Chang JJ, Chen Q, Hechter RC, Dionne-Odom J, Bruxvoort K. Changes in HIV and STI testing and diagnoses during the COVID-19 pandemic. 2022 CROI, February 12–16 and 22–24, 2022. Oral Abstract 142.
  6. DiNenno EA, Delaney KP, Pitasi MA, et al. HIV testing before and during the COVID-19 pandemic—United States, 2019–2020. MMWR 2022;71(25):820–824. doi:10.15585/mmwr.mm7125a2. PMID: 35737573
  7. Song R, Hall HI, Green TA, Szwarcwald CL, Pantazis N. Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections in the United States. J Acquir Immune Defic Syndr 2017;74(1):3–9. doi:10.1097/QAI.0000000000001151
  8. CDC. HIV Surveillance Report, 2020; vol. 33. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2022. Accessed March 13, 2023.
  9. Viguerie A, Song R, Johnson AS, Lyles CM, Hernandez A, Farnham PG. Isolating the effect of COVID-19–related disruptions on HIV diagnoses in the United States in 2020. J Acquir Immune Defic Syndr 2023;92(4):293–299. doi:10.1097/QAI.0000000000003140
  10. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. Clin Infect Dis 2017;64(2):144–149. doi:10.1093/cid/ciw701
  11. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. MMWR 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
  12. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. Public Health Rep 2020;135(2):202–210. doi:10.1177/0033354920904085
  13. U.S. Census Bureau. American Community Survey 5-year data (2009–2021). https://www.census.gov/data/developers/data-sets/acs-5year.2019.html. Published December 2022. Accessed March 13, 2023.
  14. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Updated August 2022. Accessed March 13, 2023.
  15. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. JMIR Public Health Surveill 2016;2(1):e14. doi:10.2196/publichealth.5365
  16. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. Open AIDS J 2012;6:98–107. doi:10.2174/1874613601206010098
  17. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
  18. Huang YA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of COVID-19 on HIV preexposure prophylaxis prescriptions in the United States—a time series analysis. Clin Infect Dis 2022:ciac038. doi:10.1093/cid/ciac038

Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative: National HIV Surveillance System data reported through December 2022; and preexposure prophylaxis (PrEP) data reported through September 2022. HIV Surveillance Data Tables 2022;3(4). https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/. Published May 2023. Accessed [date].

Confidential information, referrals, and educational material on HIV

CDC-INFO
1-800-232-4636 (in English, en Español)
1-888-232-6348 (TTY)
http://wwwn.cdc.gov/dcs/ContactUs/Form

Acknowledgments

This issue of HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Weiming Zhu, Ruiguang Song, Baohua Wu, Sue Reynolds, Jianmin Li, Xiaohong Hu, Pei Hou, Emily Zhu, Lei Yu, Avery Smithson, Wei Wei, Iddrisu Abdallah, Juliet Morales, Anna Baker, Andre Dailey, Shacara Johnson Lyons, Alex Viguerie, Norma Harris, Stacy Cohen, and Michael Friend (editing and desktop publishing).

The Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for their contributions to the report website.

Publication of HIV Surveillance Data Tables was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Table 1a. Estimated HIV incidence among persons aged ≥ 13 years, by selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 pandemic)a 2021a
No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI
Sex at birth
Male 29,700 2.1 28,500–30,900 29,400 2.4 28,000–30,800 28,500 2.8 26,900–30,000 27,700 3.4 25,900–29,600 25,900 4.0 23,900–27,900
Female 6,800 4.1 6,200–7,300 6,700 4.7 6,100–7,300 6,400 5.4 5,700–7,000 5,900 6.6 5,100–6,700 6,200 6.9 5,400–7,000
Age at infection (yr)
13–24 9,300 3.7 8,600–10,000 8,400 4.4 7,700–9,200 7,700 5.4 6,900–8,500 6,900 6.8 6,000–7,800 6,100 8.0 5,200–7,100
25–34 13,600 3.1 12,700–14,400 13,800 3.5 12,900–14,800 13,500 4.0 12,500–14,600 13,700 4.8 12,400–14,900 12,600 5.6 11,200–14,000
35–44 6,500 4.5 5,900–7,000 6,700 5.0 6,000–7,300 6,800 5.7 6,000–7,500 6,700 6.9 5,800–7,600 6,800 7.6 5,800–7,800
45–54 4,300 5.5 3,900–4,800 4,200 6.4 3,700–4,800 3,900 7.5 3,400–4,500 3,700 9.2 3,000–4,400 3,600 10.3 2,900–4,300
≥55 2,800 7.0 2,400–3,200 2,900 7.6 2,500–3,400 2,900 8.7 2,400–3,400 2,700 10.6 2,200–3,300 3,000 11.3 2,300–3,600
Race/ethnicity
American Indian/Alaska Native 190 26.3 90–290 180 *31.2 70–280 210 *32.7 70–340 230 *35.9 70–390 190 *45.8 20–360
Asian 600 15.3 420–780 560 18.2 360–760 540 20.3 330–760 510 25.2 260–760 470 29.6 200–750
Black/African American 15,100 2.9 14,300–16,000 15,000 3.3 14,000–15,900 14,400 3.8 13,300–15,400 13,900 4.7 12,600–15,200 13,000 5.4 11,600–14,300
Hispanic/Latinob 10,100 3.8 9,400–10,900 10,100 4.3 9,200–10,900 9,600 5.1 8,600–10,600 9,100 6.3 8,000–10,200 9,300 6.9 8,100–10,600
Native Hawaiian/other Pacific Islander 60 *49.1 0–110 … … … … … … … … … … … …
White 9,000 3.7 8,400–9,700 9,000 4.2 8,200–9,700 8,800 4.8 8,000–9,600 8,800 5.6 7,800–9,700 8,200 6.5 7,100–9,200
Multiracial 1,400 10.1 1,100–1,600 1,300 11.6 1,000–1,600 1,300 13.3 930–1,600 1,100 17.0 730–1,500 890 21.1 520–1,300
Transmission categoryc
Male-to-male sexual contactd 24,500 2.3 23,400–25,600 23,900 2.7 22,700–25,200 23,100 3.1 21,700–24,500 22,700 3.8 21,000–24,400 21,100 4.4 19,300–23,000
Injection drug usee 2,400 6.6 2,100–2,700 2,600 7.6 2,200–3,000 2,600 8.6 2,200–3,000 2,600 10.9 2,000–3,100 2,500 12.4 1,900–3,100
Male 1,300 9.7 1,100–1,600 1,500 10.3 1,200–1,800 1,400 12.4 1,100–1,800 1,500 14.7 1,100–2,000 1,400 17.6 930–1,900
Female 1,100 8.9 930–1,300 1,100 10.6 910–1,400 1,200 11.6 890–1,400 1,000 15.6 700–1,300 1,100 17.3 710–1,400
Male-to-male sexual contactdd and injection drug usee 1,400 8.8 1,200–1,600 1,500 9.2 1,200–1,800 1,500 10.4 1,200–1,800 1,400 13.2 1,000–1,700 1,300 15.2 890–1,600
Heterosexual contactf 8,100 4.2 7,400–8,800 8,000 4.8 7,200–8,800 7,600 5.5 6,800–8,400 6,900 6.8 6,000–7,800 7,100 7.2 6,100–8,100
Male 2,500 9.1 2,100–3,000 2,500 10.3 2,000–3,000 2,400 11.5 1,900–3,000 2,100 15.1 1,400–2,700 2,000 16.5 1,400–2,700
Female 5,600 4.7 5,100–6,100 5,500 5.3 5,000–6,100 5,200 6.1 4,600–5,800 4,900 7.4 4,200–5,600 5,100 7.6 4,300–5,800
Region of residence
Northeast 5,100 5.1 4,600–5,600 5,000 5.8 4,400–5,500 4,700 6.9 4,100–5,300 4,600 8.4 3,800–5,300 4,400 9.4 3,600–5,200
Midwest 4,900 5.1 4,400–5,300 4,800 5.8 4,300–5,300 4,500 6.9 3,900–5,200 4,700 8.1 3,900–5,400 4,400 9.2 3,600–5,200
South 19,000 2.6 18,000–20,000 18,800 3.0 17,700–19,900 18,400 3.5 17,100–19,600 17,200 4.3 15,700–18,600 16,700 4.8 15,100–18,200
West 7,500 4.2 6,900–8,100 7,600 4.7 6,900–8,300 7,200 5.5 6,500–8,000 7,200 6.6 6,300–8,200 6,600 7.7 5,600–7,600
Totalg 36,500 1.9 35,100–37,800 36,100 2.2 34,600–37,700 34,800 2.5 33,100–36,600 33,600 3.1 31,600–35,700 32,100 3.5 29,900–34,300

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤ 1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk(*), should be used with caution.
Estimates with an RSE > 50% are not shown and are replaced with an ellipsis (…).

a Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017‒2021 for more information.
b Hispanic/Latino persons can be of any race.
c Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
d Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
f Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
g Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

2017 2018 2019 2020 (COVID-19 pandemic)a 2021a
Area of residence No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI
Alabama 620 13.9 450–790 570 16.7 390–760 540 19.9 330–750 590 21.3 340–830 670 22.3 380–970
Alaska … … … … … … … … … … … … … … …
Arizona 800 13.0 590–1,000 820 14.9 580–1,100 760 18.1 490–1,000 720 22.9 390–1,000 780 24.0 410–1,200
Arkansas 300 23.7 160–430 260 29.6 110–410 330 28.5 150–510 360 *32.2 130–580 380 *33.4 130–640
California 4,600 5.2 4,200–5,100 4,700 5.9 4,100–5,200 4,300 7.1 3,700–4,900 4,300 8.3 3,600–5,000 4,000 9.8 3,200–4,700
Colorado 440 17.1 290–580 400 21.0 230–560 460 21.9 260–650 370 *30.3 150–590 490 28.6 210–760
Connecticut 250 22.5 140–350 210 28.6 90–320 160 *37.9 40–290 200 *40.4 40–360 180 *44.4 20–330
Delaware 120 *33.1 40–200 90 *48.7 0–170 … … … … … … … … …
District of Columbia 230 24.8 120–340 230 26.7 110–350 190 *33.5 70–320 140 *47.9 10–280 150 *46.8 10–300
Florida 4,400 5.3 3,900–4,800 4,100 6.3 3,600–4,700 3,900 7.4 3,400–4,500 3,800 9.0 3,100–4,500 3,700 9.9 3,000–4,400
Georgia 2,600 7.4 2,200–3,000 2,500 8.7 2,100–3,000 2,400 10.3 1,900–2,900 2,300 12.9 1,700–2,900 2,300 14.1 1,700–2,900
Hawaii 80 *41.5 10–150 … … … … … … … … … … … …
Idahob … … … … … … … … … … … … … … …
Illinois 1,300 9.8 1,000–1,500 1,300 11.1 1,000–1,600 1,200 13.6 850–1,500 1,100 16.5 780–1,500 1,100 18.8 680–1,500
Indiana 510 16.0 350–670 550 17.4 360–740 500 21.5 290–710 630 22.4 350–900 540 26.4 260–810
Iowa 100 *36.8 30–180 120 *37.7 30–210 140 *39.2 30–250 … … … … … …
Kansas 90 *43.0 10–170 120 *40.8 20–210 190 *33.4 60–310 160 *43.7 20–300 … … …
Kentucky 330 19.9 200–460 440 18.9 270–600 380 24.3 200–560 390 29.3 170–620 420 *31.7 160–680
Louisiana 920 12.0 700–1,100 950 13.3 700–1,200 840 16.8 560–1,100 880 19.6 540–1,200 760 23.1 420–1,100
Maine … … … … … … … … … … … … … … …
Maryland 770 13.4 570–970 840 13.8 610–1,100 730 16.9 490–970 680 20.3 410–940 630 23.3 340–910
Massachusetts 500 15.1 350–650 590 15.0 420–760 460 19.8 280–640 350 26.6 170–530 370 28.6 160–570
Michigan 660 13.7 480–840 640 15.7 440–840 600 18.7 380–820 630 21.6 360–890 590 24.7 310–880
Minnesota 250 22.6 140–360 310 22.7 170–450 270 27.8 120–420 240 *34.9 80–410 230 *39.9 50–420
Mississippi 420 18.6 270–580 440 21.2 260–630 470 23.9 250–690 460 28.9 200–720 420 *36.4 120–730
Missouri 540 13.4 400–690 480 16.8 320–640 460 19.2 290–630 440 24.6 230–660 470 24.2 250–700
Montana … … … … … … … … … … … … … … …
Nebraska 110 *35.2 30–180 … … … … … … … … … … … …
Nevada 530 16.1 370–700 590 17.7 380–790 590 21.0 350–830 610 25.3 300–910 520 *31.3 200–840
New Hampshire … … … … … … … … … … … … … … …
New Jerseyb 1,100 12.2 820–1,300 920 15.2 650–1,200 1,000 16.0 680–1,300 970 20.3 580–1,400 1,100 18.9 670–1,500
New Mexico 140 26.3 70–210 190 25.6 90–280 160 *32.1 60–270 140 *43.0 20–260 130 *48.8 10–260
New York 2,200 7.6 1,900–2,600 2,000 9.1 1,700–2,400 1,900 10.6 1,500–2,300 1,900 12.4 1,400–2,400 1,700 14.5 1,200–2,200
North Carolina 1,300 9.5 1,000–1,500 1,200 11.0 970–1,500 1,400 11.5 1,100–1,700 1,200 15.5 800–1,500 1,100 17.3 700–1,400
North Dakota … … … … … … … … … … … … … … …
Ohio 920 11.7 710–1,100 890 13.6 660–1,100 860 15.8 590–1,100 810 18.7 510–1,100 850 20.8 500–1,200
Oklahoma 340 18.9 220–470 340 22.3 190–480 430 21.9 250–620 390 28.4 170–610 370 *33.5 130–610
Oregon 190 26.1 90–290 170 *31.4 70–280 190 *33.2 70–320 210 *38.8 50–370 230 *42.6 40–420
Pennsylvaniab 980 12.9 740–1,200 1,000 13.3 760–1,300 860 15.8 600–1,100 850 18.8 540–1,200 650 23.8 350–950
Puerto Ricob 410 18.6 260–560 350 22.4 200–510 320 26.7 150–490 280 *33.6 100–470 280 *35.4 90–470
Rhode Island 80 *34.5 30–140 60 *47.7 0–120 … … … … … … … … …
South Carolina 690 15.0 480–890 700 17.2 460–930 670 20.2 400–930 630 23.7 340–920 650 27.5 300–1,000
South Dakota … … … … … … … … … … … … … … …
Tennessee 750 12.0 570–930 740 13.8 540–940 800 14.5 570–1,000 700 19.1 440–960 720 20.2 430–1,000
Texas 4,400 5.5 3,900–4,800 4,500 6.2 3,900–5,000 4,500 7.0 3,900–5,100 4,200 8.8 3,500–5,000 4,000 10.0 3,300–4,800
Utah 130 *34.1 40–220 140 *37.1 40–240 140 *42.0 30–260 … … … … … …
Vermont … … … … … … … … … … … … … … …
Virginia 850 12.8 630–1,100 820 14.9 580–1,100 800 17.1 530–1,100 720 21.3 420–1,000 640 24.4 330–950
Washington 450 17.1 300–600 540 17.5 360–730 510 21.0 300–720 450 27.2 210–690 470 *30.2 190–750
West Virginia 110 *37.7 30–200 170 *35.4 50–300 260 *34.1 90–430 … … … … … …
Wisconsin 250 23.1 130–360 210 29.5 90–330 220 *33.1 80–360 300 *31.9 110–490 230 *41.5 40–430
Wyoming … … … … … … … … … … … … … … …

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥ 13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤ 1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk(*), should be used with caution.
Estimates with an RSE > 50% are not shown and are replaced with an ellipsis (…).

a Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017‒2021 for more information.
b Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

2017 2018 2019 2020 (COVID-19 pandemic)a 2021a
Area of residence No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI No. RSE 95% CI
Arizona
Maricopa County 570 15.7 390–740 550 18.5 350–750 510 22.2 290–730 470 28.9 200–740 460 *31.9 170–750
California
Alameda County 190 25.7 90–280 190 28.5 80–300 200 *31.9 80–330 150 *42.5 30–280 170 *45.5 20–320
Los Angeles County 1,500 9.0 1,200–1,800 1,500 10.3 1,200–1,800 1,400 12.1 1,100–1,700 1,400 14.2 980–1,700 1,200 17.1 790–1,600
Orange County 290 20.5 170–410 280 23.6 150–410 230 29.8 90–360 280 *31.5 110–450 230 *38.7 60–410
Riverside County 270 21.5 150–380 290 23.4 150–420 260 27.8 120–410 280 *31.3 110–450 240 *37.9 60–430
Sacramento County 220 23.6 120–320 220 26.8 100–330 210 *31.4 80–330 180 *39.2 40–320 … … …
San Bernardino County 270 21.1 160–390 260 24.5 140–390 310 25.5 160–470 310 29.8 130–490 280 *35.5 80–470
San Diego County 430 16.8 290–580 420 19.1 270–580 420 22.1 240–600 370 27.2 170–570 410 29.3 170–640
San Francisco County 170 26.8 80–260 160 *31.5 60–260 120 *41.7 20–210 120 *47.0 10–240 140 *49.9 0–280
District of Columbia 230 24.8 120–340 230 26.7 110–350 190 *33.5 70–320 140 *47.9 10–280 150 *46.8 10–300
Florida
Broward County 650 13.4 480–820 530 17.1 350–700 540 19.0 340–750 510 23.7 270–740 500 26.2 240–760
Duval County 270 20.8 160–380 240 25.0 120–370 220 *30.1 90–350 280 *32.0 100–450 230 *38.9 50–400
Hillsborough County 300 19.8 180–410 270 23.8 140–400 240 28.7 100–370 290 *31.3 110–470 180 *44.2 20–330
Miami-Dade County 1,100 10.1 910–1,400 1,100 12.1 800–1,300 980 14.2 700–1,200 850 18.3 550–1,200 870 19.8 530–1,200
Orange County 430 16.5 290–560 410 19.5 250–560 450 20.9 270–640 440 25.5 220–670 460 27.4 210–700
Palm Beach County 260 21.2 150–360 260 24.5 130–380 240 28.7 100–370 300 *30.8 120–480 230 *38.3 60–410
Pinellas County 160 26.6 80–250 140 *33.4 50–230 150 *36.6 40–250 160 *42.3 30–290 … … …
Georgia
Cobb County 190 26.1 90–280 160 *33.0 60–260 190 *34.7 60–320 170 *45.1 20–330 … … …
DeKalb County 360 18.8 230–490 390 20.9 230–560 320 26.7 150–490 290 *34.5 100–490 320 *37.1 90–550
Fulton County 590 14.7 420–760 620 16.8 410–820 530 21.0 310–750 590 24.5 300–870 530 28.7 230–830
Gwinnett County 160 27.9 70–250 150 *34.3 50–250 190 *34.4 60–330 … … … … … …
Illinois
Cook County 910 11.3 710–1,100 890 13.1 660–1,100 810 15.9 560–1,100 830 18.8 520–1,100 780 21.4 450–1,100
Indiana
Marion County 220 22.2 130–320 220 25.0 110–330 230 28.5 100–360 240 *33.4 80–400 210 *39.7 50–370
Louisiana
East Baton Rouge Parish 170 26.3 80–250 180 28.5 80–280 160 *34.2 50–280 120 *49.2 0–240 … … …
Orleans Parish 150 27.9 70–230 150 *30.6 60–240 130 *38.4 30–230 … … … … … …
Maryland
Baltimore City 200 26.9 90–300 210 27.2 100–330 130 *40.4 30–240 180 *40.4 40–310 150 *48.0 10–280
Montgomery County 100 *37.8 30–170 90 *41.1 20–170 100 *47.6 10–180 … … … … … …–…
Prince George’s County 200 26.3 100–310 260 24.8 130–380 230 *30.3 90–370 170 *41.6 30–300 200 *41.1 40–360
Massachusetts
Suffolk County 120 26.0 60–180 120 27.5 60–190 120 *31.1 50–190 120 *33.9 40–200 120 *38.7 30–210
Michigan
Wayne County 280 20.1 170–390 270 23.8 140–390 280 25.8 140–420 270 *31.1 110–440 220 *39.7 50–390
Nevada
Clark County 480 16.3 330–630 520 18.3 330–700 490 22.4 270–700 530 25.7 260–800 460 *32.2 170–740
New Jersey
Essex Countyb 310 21.4 180–440 220 29.9 90–340 200 *35.9 60–330 230 *38.6 60–400 270 *34.3 90–450
Hudson Countyb 160 29.7 70–250 150 *35.7 50–260 110 *48.0 10–210 140 *48.7 10–280 130 *49.0 0–260
New York
Bronx County 400 17.2 270–540 390 19.4 240–540 370 23.1 200–540 390 26.0 190–580 380 29.1 160–600
Kings County 470 15.8 330–620 450 18.4 290–610 400 22.2 230–580 380 26.2 180–570 360 *30.0 150–570
New York County 350 18.4 220–470 310 22.1 170–440 270 26.8 130–420 300 29.4 130–470 260 *35.1 80–440
Queens County 330 18.7 210–460 320 21.5 190–460 250 28.2 110–390 290 *30.0 120–460 270 *34.7 80–450
North Carolina
Mecklenburg County 290 18.7 180–390 240 23.6 130–350 290 23.2 160–420 250 *31.2 100–400 190 *37.9 50–330
Ohio
Cuyahoga County 130 *30.4 50–210 130 *33.7 40–220 130 *38.9 30–230 160 *38.6 40–290 160 *46.8 10–300
Franklin County 190 25.0 100–280 200 27.5 90–310 210 *30.7 80–330 180 *37.1 50–310 150 *47.3 10–300
Hamilton County 150 27.9 70–230 140 *32.9 50–230 130 *39.3 30–220 120 *44.7 10–230 … … …
Pennsylvania
Philadelphia County 390 16.1 270–520 410 17.4 270–550 410 19.4 250–560 280 *30.7 110–440 290 *31.3 110–470
Puerto Rico
San Juan Municipiob 100 *35.2 30–170 70 *48.4 0–130 80 *47.1 10–150 … … … … … …
Tennessee
Shelby County 240 20.0 150–340 250 21.9 140–360 280 23.3 150–400 210 *32.6 80–350 220 *33.6 80–370
Texas
Bexar County 300 20.2 180–420 320 22.5 180–460 370 23.9 200–540 380 28.5 170–600 310 *35.2 90–520
Dallas County 830 12.3 630–1,000 820 14.1 600–1,100 650 17.9 420–880 730 20.5 440–1,000 750 22.5 420–1,100
Harris County 1,100 10.4 910–1,400 1,100 12.0 860–1,400 1,200 13.5 850–1,500 1,100 16.9 730–1,400 1,000 19.0 660–1,400
Tarrant County 300 20.6 180–420 280 23.8 150–420 380 23.5 210–560 29.2 150 570–320 320 *34.6 100–530
Travis County 210 24.7 110–310 240 26.0 120–360 180 *34.4 60–300 *42.7 30 310–190 190 *45.1 20–350
Washington
King County 210 25.8 100–310 260 25.0 130–390 220 *33.2 80–360 *39.6 50 370–200 200 *46.3 20–390

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥ 13 years at diagnosis.
Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤ 1,000 to reflect model uncertainty.
Estimates with an RSE 30%‒50%, preceded by an asterisk(*), should be used with caution.
Estimates with an RSE > 50% are not shown and are replaced with an ellipsis (…).

a Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017‒2021 for more information.
b Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

  2017 2018
  Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
  No. RSE 95% CI No.b % RSE 95% CI No. RSE 95% CI No.b % RSE 95% CI
Sex at birth
Male 886,200 0.3 880,100–892,200 753,766 85.1 0.4 84.5–85.6 904,500 0.4 898,300–910,800 772,969 85.5 0.4 84.9–86.1
Female  256,600 0.6 253,500–259,600 228,901 89.2 0.6 88.2–90.3 259,800 0.6 256,700–263,000 232,542 89.5 0.6 88.4–90.6
Age (yr)
13–24 65,200 1.0 63,900–66,500 27,742 42.6 1.0 41.7–43.4 59,200 1.2 57,800–60,600 26,607 45.0 1.2 43.9–46.0
25–34 203,900 0.5 201,900–206,000 148,377 72.8 0.5 72.0–73.5 211,200 0.5 209,000–213,500 153,232 72.5 0.5 71.8–73.3
35–44 216,800 0.4 214,900–218,600 186,686 86.1 0.4 85.4–86.9 220,200 0.5 218,300–222,200 189,167 85.9 0.5 85.1–86.7
45–54 313,600 0.3 311,400–315,700 291,493 93.0 0.3 92.3–93.6 301,000 0.4 298,800–303,100 279,604 92.9 0.4 92.2–93.6
≥ 55 343,200 0.4 340,400–346,100 328,369 95.7 0.4 94.9–96.5 372,800 0.4 369,800–375,800 356,901 95.7 0.4 95.0–96.5
Race/ethnicity
American Indian/Alaska Native 3,500 5.6 3,100–3,900 2,730 77.3 5.6 69.7–86.7 3,700 5.6 3,300–4,100 2,853 77.9 5.7 70.2–87.5
Asianc 16,500 2.3 15,800–17,300 13,516 81.8 2.3 78.3–85.7 17,100 2.3 16,300–17,900 14,375 84.1 2.3 80.5–88.1
Black/African American 461,000 0.5 456,700–465,400 395,740 85.8 0.5 85.0–86.7 469,600 0.5 465,100–474,100 404,951 86.2 0.5 85.4–87.1
Hispanic/Latinod 268,800 0.6 265,700–272,000 223,165 83.0 0.6 82.0–84.0 277,000 0.6 273,700–280,200 231,101 83.4 0.6 82.5–84.4
Native Hawaiian/other Pacific Islander 990 9.9 800–1,200 739 74.4 10.3 62.3–92.3 1,000 10.1 830–1,200 784 75.8 10.5 63.3–94.4
White 329,600 0.6 325,700–333,400 291,194 88.4 0.6 87.3–89.4 333,600 0.6 329,600–337,500 295,534 88.6 0.6 87.6–89.7
Multiracial 61,600 1.2 60,200–63,000 54,920 89.2 1.2 87.2–91.3 61,800 1.2 60,400–63,300 55,250 89.4 1.2 87.3–91.5
Transmission categorye
Male-to-male sexual contactf 655,100 0.4 650,000–660,200 549,064 83.8 0.4 83.2–84.5 673,000 0.4 667,700–678,200 567,472 84.3 0.4 83.7–85.0
Injection drug useg 125,900 1.1 123,300–128,500 116,784 92.8 1.1 90.9–94.7 125,200 1.1 122,500–127,800 115,950 92.6 1.1 90.7–94.6
Male 73,200 1.5 71,100–75,300 67,774 92.6 1.5 90.1–95.3 72,600 1.5 70,500–74,700 67,101 92.4 1.5 89.8–95.2
Female 52,700 1.5 51,200–54,200 49,011 93.0 1.5 90.4–95.8 52,600 1.5 51,000–54,100 48,850 92.9 1.5 90.2–95.8
Male-to-male sexual contactf and injection drug useg 63,400 1.3 61,800–65,000 58,001 91.5 1.3 89.2–93.9 63,500 1.3 61,900–65,200 58,116 91.5 1.3 89.2–93.9
Heterosexual contacth 294,500 0.6 291,200–297,700 255,234 86.7 0.6 85.7–87.7 298,900 0.6 295,500–302,200 260,362 87.1 0.6 86.1–88.1
Male 92,200 1.1 90,300–94,200 76,847 83.3 1.1 81.6–85.1 93,200 1.1 91,200–95,300 78,210 83.9 1.1 82.1–85.8
Female 202,200 0.7 199,600–204,800 178,387 88.2 0.7 87.1–89.4 205,600 0.7 202,900–208,300 182,152 88.6 0.7 87.4–89.8
Region of residence
Northeast 248,600 0.7 245,300–251,800 226,712 91.2 0.7 90.0–92.4 250,000 0.7 246,700–253,400 228,784 91.5 0.7 90.3–92.7
Midwest 139,100 0.9 136,800–141,500 117,129 84.2 0.9 82.8–85.6 142,000 0.9 139,600–144,400 120,165 84.6 0.9 83.2–86.1
South 527,000 0.4 522,500–531,600 443,937 84.2 0.4 83.5–85.0 538,900 0.4 534,200–543,600 456,294 84.7 0.4 83.9–85.4
West 228,000 0.7 225,000–231,000 194,889 85.5 0.7 84.4–86.6 233,400 0.7 230,300–236,500 200,268 85.8 0.7 84.7–87.0
Totali 1,142,700 0.3 1,135,900–1,149,500 982,667 86.0 0.3 85.5–86.5 1,164,400 0.3 1,157,400–1,171,400 1,005,511 86.4 0.3 85.8–86.9
  2019 2020 (COVID-19 pandemic)a
  Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
  No. RSE 95% CI No.b % RSE 95% CI No. RSE 95% CI No.b % RSE 95% CI
Sex at birth
Male 921,900 0.4 915,400–928,400 791,399 85.8 0.4 85.2–86.5 932,300 0.4 925,600–939,100 802,910 86.1 0.4 85.5–86.7
Female  262,900 0.6 259,700–266,100 236,166 89.8 0.6 88.7–90.9 263,600 0.6 260,300–267,000 237,346 90.0 0.6 88.9–91.2
Age (yr)
13–24 53,500 1.4 52,000–55,000 25,934 48.5 1.4 47.2–49.9 46,900 1.7 45,300–48,500 24,027 51.3 1.8 49.6–53.1
25–34 216,200 0.6 213,800–218,700 156,651 72.4 0.6 71.6–73.3 217,100 0.7 214,300–219,900 156,512 72.1 0.7 71.2–73.0
35–44 225,100 0.5 223,000–227,200 192,529 85.5 0.5 84.7–86.4 230,200 0.5 227,900–232,600 195,916 85.1 0.5 84.2–86.0
45–54 287,400 0.4 285,300–289,600 266,664 92.8 0.4 92.1–93.5 273,800 0.4 271,600–276,000 253,579 92.6 0.4 91.9–93.4
≥ 55 402,600 0.4 399,500–405,700 385,787 95.8 0.4 95.1–96.6 428,000 0.4 424,700–431,200 410,222 95.9 0.4 95.1–96.6
Race/ethnicity
American Indian/Alaska Native 3,800 5.7 3,400–4,200 2,990 78.4 5.8 70.6–88.2 3,900 5.9 3,500–4,400 3,099 78.8 6.0 70.6–89.1
Asianc 17,700 2.3 16,900–18,500 15,118 85.6 2.3 81.9–89.7 18,100 2.4 17,200–18,900 15,721 87.1 2.4 83.2–91.3
Black/African American 477,600 0.5 473,000–482,200 413,920 86.7 0.5 85.8–87.5 481,700 0.5 476,900–486,500 418,714 86.9 0.5 86.1–87.8
Hispanic/Latinod 284,700 0.6 281,200–288,100 239,069 84.0 0.6 83.0–85.0 289,500 0.6 285,900–293,200 244,303 84.4 0.6 83.3–85.5
Native Hawaiian/other Pacific Islander 1,100 10.2 850–1,300 830 78.0 10.7 64.9–97.6 1,100 10.7 880–1,300 882 79.8 10.9 66.0–100
White 337,300 0.6 333,300–341,300 299,443 88.8 0.6 87.7–89.8 339,300 0.6 335,100–343,400 301,619 88.9 0.6 87.8–90.0
Multiracial 62,000 1.2 60,600–63,500 55,536 89.5 1.2 87.4–91.7 61,700 1.3 60,200–63,200 55,260 89.6 1.3 87.4–91.8
Transmission categorye
Male-to-male sexual contactf 689,900 0.4 684,500–695,300 585,215 84.8 0.4 84.2–85.5 701,900 0.4 696,200–707,600 598,237 85.2 0.4 84.5–85.9
Injection drug useg 124,500 1.1 121,900–127,200 115,253 92.6 1.1 90.6–94.6 123,000 1.1 120,200–125,700 113,525 92.3 1.1 90.3–94.4
Male 72,100 1.5 69,900–74,200 66,494 92.2 1.5 89.6–95.1 71,100 1.6 68,900–73,300 65,327 91.9 1.6 89.1–94.8
Female 52,400 1.5 50,900–54,000 48,759 93.0 1.5 90.2–95.9 51,800 1.6 50,200–53,500 48,198 93.0 1.6 90.1–96.0
Male-to-male sexual contactf and injection drug useg 63,600 1.3 62,000–65,300 58,324 91.6 1.3 89.3–94.1 63,200 1.4 61,500–64,900 57,858 91.5 1.4 89.1–94.1
Heterosexual contacth 302,900 0.6 299,400–306,300 265,124 87.5 0.6 86.5–88.6 304,000 0.6 300,400–307,600 267,001 87.8 0.6 86.8–88.9
Male 94,100 1.1 92,000–96,200 79,292 84.3 1.1 82.4–86.2 93,900 1.2 91,700–96,100 79,440 84.6 1.2 82.6–86.6
Female 208,800 0.7 206,000–211,500 185,832 89.0 0.7 87.8–90.2 210,100 0.7 207,200–212,900 187,561 89.3 0.7 88.1–90.5
Region of residence
Northeast 250,900 0.7 247,500–254,300 230,293 91.8 0.7 90.6–93.0 250,200 0.7 246,700–253,700 229,844 91.9 0.7 90.6–93.2
Midwest 144,500 0.9 142,000–147,000 122,883 85.0 0.9 83.6–86.5 146,400 0.9 143,800–149,000 124,830 85.3 0.9 83.8–86.8
South 550,900 0.5 546,000–555,800 468,902 85.1 0.5 84.4–85.9 558,000 0.5 552,900–563,100 476,871 85.5 0.5 84.7–86.3
West 238,500 0.7 235,300–241,700 205,487 86.2 0.7 85.0–87.3 241,400 0.7 238,100–244,800 208,711 86.4 0.7 85.3–87.7
Totali 1,184,800 0.3 1,177,600–1,192,100 1,027,565 86.7 0.3 86.2–87.3 1,196,000 0.3 1,188,400–1,203,500 1,040,256 87.0 0.3 86.4–87.5
  2021a
  Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
  No. RSE 95% CI No.b % RSE 95% CI
Sex at birth
Male 946,500 0.4 939,400–953,500 819,141 86.5 0.4 85.9–87.2
Female  265,900 0.7 262,500–269,300 239,759 90.2 0.7 89.0–91.3
Age (yr)
13–24 41,900 2.1 40,200–43,700 23,671 56.4 2.1 54.2–58.9
25–34 217,100 0.7 214,000–220,200 157,035 72.3 0.7 71.3–73.4
35–44 238,300 0.6 235,700–241,000 202,019 84.8 0.6 83.8–85.7
45–54 263,000 0.4 260,700–265,300 243,001 92.4 0.4 91.6–93.2
≥ 55 452,000 0.4 448,600–455,400 433,174 95.8 0.4 95.1–96.6
Race/ethnicity
American Indian/Alaska Native 4,100 6.1 3,600–4,500 3,245 80.1 6.2 71.5–91.0
Asianc 18,600 2.4 17,700–19,400 16,455 88.7 2.5 84.6–93.1
Black/African American 487,500 0.5 482,500–492,500 425,519 87.3 0.5 86.4–88.2
Hispanic/Latinod 297,200 0.7 293,400–301,100 252,342 84.9 0.7 83.8–86.0
Native Hawaiian/other Pacific Islander 1,200 11.1 950–1,400 948 80.7 10.6 66.3–100
White 342,000 0.6 337,800–346,300 304,871 89.1 0.6 88.0–90.3
Multiracial 61,200 1.3 59,600–62,800 54,864 89.6 1.3 87.4–92.0
Transmission categorye
Male-to-male sexual contactf 716,900 0.4 710,900–722,900 615,019 85.8 0.4 85.1–86.5
Injection drug useg 121,900 1.2 119,200–124,700 112,395 92.2 1.2 90.1–94.3
Male 70,400 1.6 68,100–72,600 64,530 91.7 1.6 88.8–94.7
Female 51,600 1.6 49,900–53,200 47,864 92.8 1.6 89.9–95.9
Male-to-male sexual contactf and injection drug useg 62,900 1.4 61,100–64,600 57,559 91.6 1.4 89.1–94.2
Heterosexual contacth 306,700 0.6 303,000–310,500 270,255 88.1 0.6 87.0–89.2
Male 94,100 1.2 91,800–96,400 79,991 85.0 1.2 82.9–87.1
Female 212,600 0.7 209,600–215,600 190,265 89.5 0.7 88.3–90.8
Region of residence
Northeast 250,600 0.7 247,100–254,200 230,704 92.0 0.7 90.7–93.4
Midwest 148,800 0.9 146,000–151,500 127,435 85.7 0.9 84.1–87.3
South 567,800 0.5 562,400–573,200 487,976 85.9 0.5 85.1–86.8
West 245,200 0.7 241,700–248,700 212,785 86.8 0.7 85.6–88.0
Totali 1,212,400 0.3 1,204,500–1,220,200 1,058,900 87.3 0.3 86.8–87.9

Abbreviations: RSE, relative standard error; CI, confidence interval; CDC, the Centers for Disease Control and Prevention [footnotes only]l; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates for the year 2021 data are preliminary and based on deaths reported to CDC as of December 2022. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥ 13 years at diagnosis.

a Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017‒2021 for more information.
b Reported to the National HIV Surveillance System.
c Includes Asian/Pacific Islander legacy cases.
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

  2017 2018
  Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
  No. RSE 95% CI No.b % RSE 95% CI No. RSE 95% CI No.b % RSE 95% CI
Alabama 15,600 2.6 14,800–16,400 12,899 82.5 2.6 78.6–86.9 16,000 2.6 15,200–16,800 13,331 83.2 2.6 79.1–87.6
Alaska 820 10.8 710–1,000 705 85.7 8.7 70.7–100 810 11.2 690–990 694 85.2 9.0 69.8–100
Arizona 18,800 2.2 18,000–19,600 15,606 83.1 2.2 79.6–86.9 19,500 2.2 18,600–20,300 16,246 83.4 2.3 79.9–87.2
Arkansas 6,900 3.8 6,400–7,400 5,458 79.0 3.9 73.5–85.5 7,000 3.9 6,500–7,600 5,614 79.8 4.0 74.1–86.4
California 146,700 0.8 144,300–149,100 126,922 86.5 0.8 85.1–88.0 149,300 0.9 146,800–151,800 129,640 86.8 0.9 85.4–88.3
Colorado 13,800 2.6 13,100–14,500 11,969 86.7 2.6 82.5–91.3 14,300 2.6 13,500–15,000 12,422 87.1 2.6 82.9–91.7
Connecticut 11,200 3.1 10,500–11,900 10,138 90.5 3.1 85.3–96.4 11,300 3.1 10,600–12,000 10,281 91.1 3.2 85.8–97.0
Delaware 3,700 5.3 3,300–4,100 3,218 86.9 5.4 78.7–97.0 3,700 5.4 3,300–4,100 3,240 87.1 5.5 78.7–97.4
District of Columbia 15,100 2.7 14,300–15,900 14,039 93.0 2.7 88.4–98.1 14,900 2.7 14,100–15,700 13,917 93.2 2.7 88.5–98.5
Florida 125,800 0.9 123,600–128,100 107,755 85.6 0.9 84.1–87.2 127,700 0.9 125,400–130,000 109,843 86.0 0.9 84.5–87.6
Georgia 63,600 1.2 62,100–65,100 52,255 82.2 1.2 80.3–84.2 65,600 1.2 64,000–67,200 54,270 82.7 1.2 80.8–84.7
Hawaii 2,700 6.4 2,400–3,000 2,376 88.5 6.2 78.6–100 2,600 6.7 2,300–3,000 2,324 88.8 6.2 78.5–100
Idahoc 1,500 10.7 1,200–1,800 1,093 74.2 11.2 61.3–93.9 1,500 11.2 1,200–1,900 1,143 74.4 11.8 61.1–95.4
Illinois 39,800 1.6 38,600–41,100 34,336 86.2 1.6 83.5–89.1 40,500 1.6 39,200–41,900 35,131 86.6 1.7 83.9–89.5
Indiana 13,000 2.7 12,300–13,700 10,859 83.4 2.7 79.1–88.1 13,400 2.8 12,700–14,100 11,209 83.6 2.8 79.3–88.4
Iowa 3,100 5.1 2,800–3,400 2,634 84.4 5.2 76.7–93.9 3,200 5.2 2,900–3,600 2,744 84.7 5.2 76.9–94.3
Kansas 3,600 5.3 3,200–4,000 2,972 82.5 5.4 74.7–92.2 3,600 5.5 3,200–4,000 3,043 83.7 5.6 75.6–93.8
Kentucky 8,400 3.3 7,900–9,000 6,903 81.8 3.3 76.9–87.4 8,700 3.3 8,200–9,300 7,154 81.8 3.3 76.8–87.4
Louisiana 24,100 2.1 23,100–25,100 20,019 83.2 2.1 79.8–86.8 24,500 2.2 23,500–25,600 20,491 83.5 2.2 80.1–87.2
Maine 1,800 7.5 1,500–2,000 1,537 86.5 7.3 75.4–100 1,800 7.6 1,600–2,100 1,585 87.0 7.1 75.7–100
Maryland 36,100 1.7 34,900–37,300 32,102 89.0 1.7 86.1–92.0 36,400 1.7 35,200–37,700 32,609 89.5 1.7 86.6–92.6
Massachusetts 22,000 2.1 21,100–22,900 19,945 90.7 2.1 87.2–94.6 22,200 2.1 21,300–23,100 20,248 91.1 2.1 87.5–95.0
Michigan 18,300 2.5 17,400–19,200 15,449 84.5 2.5 80.6–88.8 18,500 2.5 17,600–19,400 15,762 85.1 2.5 81.1–89.5
Minnesota 9,300 3.0 8,800–9,900 8,140 87.1 3.1 82.2–92.7 9,600 3.0 9,100–10,200 8,416 87.3 3.1 82.4–92.9
Mississippid 11,000 3.1 10,300–11,700 9,089 82.5 3.2 77.7–87.9 11,200 3.2 10,400–11,900 9,259 83.0 3.2 78.1–88.6
Missouri 14,000 2.7 13,300–14,700 12,140 86.7 2.7 82.4–91.5 14,300 2.7 13,600–15,100 12,445 86.7 2.7 82.4–91.5
Montana 680 10.2 600–820 604 88.9 7.4 74.1–100 700 10.2 630–840 628 90.2 7.1 75.1–100
Nebraska 2,500 6.0 2,200–2,800 2,085 83.7 6.1 74.9–95.0 2,500 6.1 2,200–2,800 2,128 84.7 6.2 75.6–96.4
Nevada 11,600 2.8 10,900–12,200 9,397 81.2 2.8 77.0–85.9 12,200 2.8 11,600–12,900 9,975 81.5 2.8 77.3–86.2
New Hampshire 1,300 8.7 1,200–1,500 1,156 88.3 7.1 75.5–100 1,400 8.5 1,200–1,600 1,224 89.1 6.8 76.4–100
New Jerseyc 38,300 1.9 36,900–39,800 33,765 88.1 1.9 84.9–91.4 38,400 1.9 36,900–39,800 33,888 88.3 1.9 85.1–91.8
New Mexico 3,900 4.6 3,600–4,300 3,382 86.6 4.7 79.4–95.2 4,100 4.5 3,800–4,500 3,579 86.6 4.6 79.5–95.0
New York 133,000 0.9 130,600–135,300 122,472 92.1 0.9 90.5–93.8 133,200 0.9 130,800–135,600 123,159 92.4 0.9 90.8–94.1
North Carolina 35,600 1.6 34,500–36,700 30,380 85.4 1.6 82.8–88.2 36,600 1.6 35,400–37,700 31,306 85.6 1.6 83.0–88.4
North Dakota 630 13.7 460–800 404 64.3 14.8 50.7–88.1 680 13.9 500–870 442 64.8 15.0 50.9–89.2
Ohio 25,700 1.9 24,700–26,700 21,502 83.7 1.9 80.6–87.0 26,200 2.0 25,200–27,200 22,066 84.3 2.0 81.2–87.6
Oklahoma 7,300 3.8 6,800–7,900 5,930 81.1 3.8 75.5–87.6 7,500 3.8 7,000–8,100 6,091 80.9 3.8 75.3–87.4
Oregon 7,700 3.3 7,200–8,200 6,808 88.4 3.4 83.0–94.6 7,800 3.4 7,300–8,300 6,983 89.3 3.4 83.7–95.6
Pennsylvaniac 38,700 1.6 37,500–39,900 34,533 89.2 1.6 86.5–92.2 39,300 1.7 38,100–40,600 35,164 89.4 1.7 86.6–92.4
Puerto Ricoc,d 17,500 3.0 16,500–18,500 15,628 89.3 3.0 84.4–94.9 17,300 3.1 16,200–18,300 15,483 89.7 3.1 84.6–95.4
Rhode Island 2,800 5.8 2,500–3,100 2,498 90.0 5.4 80.8–100 2,800 5.8 2,500–3,100 2,549 90.6 5.3 81.3–100
South Carolina 19,600 2.3 18,700–20,500 16,214 82.8 2.3 79.2–86.7 20,000 2.3 19,100–20,900 16,683 83.3 2.3 79.6–87.3
South Dakota 740 12.0 570–910 565 76.8 12.6 62.1–100 770 12.3 600–960 600 77.7 12.3 62.6–100
Tennessee 19,600 2.3 18,700–20,400 16,564 84.7 2.3 81.1–88.6 20,200 2.2 19,300–21,000 17,166 85.2 2.3 81.6–89.1
Texas 106,300 1.0 104,300–108,300 87,340 82.2 1.0 80.6–83.7 109,800 1.0 107,800–111,900 90,838 82.7 1.0 81.2–84.3
Utah 3,300 5.4 3,000–3,700 2,725 82.0 5.5 74.2–91.7 3,500 5.3 3,200–3,900 2,910 82.5 5.4 74.7–92.1
Vermont 730 10.0 670–880 668 91.0 6.7 76.0–100 740 10.1 690–890 686 92.4 6.3 77.2–100
Virginia 25,700 2.0 24,700–26,700 21,991 85.5 2.0 82.2–89.0 26,300 2.0 25,200–27,300 22,597 86.0 2.0 82.7–89.5
Washington 14,900 2.5 14,200–15,600 12,980 87.1 2.5 83.0–91.6 15,400 2.5 14,600–16,100 13,381 87.1 2.5 83.1–91.7
West Virginia 2,200 6.8 1,900–2,500 1,781 79.8 6.9 70.4–92.0 2,400 6.8 2,100–2,700 1,885 77.9 6.9 68.8–89.9
Wisconsin 7,100 3.7 6,600–7,600 6,043 85.4 3.7 79.7–92.1 7,200 3.7 6,700–7,700 6,179 85.7 3.7 79.9–92.4
Wyoming 370 15.1 320–480 322 86.8 9.7 67.0–100 390 14.7 340–510 343 87.1 9.5 67.6–100
  2019 2020 (COVID-19 pandemic)a
  Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
  No. RSE 95% CI No.b % RSE 95% CI No. RSE 95% CI No.b % RSE 95% CI
Alabama 16,300 2.6 15,500–17,200 13,721 84.0 2.6 79.9–88.6 16,600 2.7 15,700–17,500 13,992 84.4 2.7 80.1–89.1
Alaska 840 11.3 710–1,000 711 84.6 9.3 69.2–100 850 11.7 720–1,000 721 84.9 9.3 69.1–100
Arizona 20,200 2.3 19,300–21,100 16,969 83.9 2.3 80.3–87.9 20,700 2.4 19,800–21,700 17,472 84.3 2.4 80.6–88.4
Arkansas 7,300 4.0 6,700–7,900 5,815 79.9 4.1 74.1–86.7 7,500 4.2 6,800–8,100 5,948 79.8 4.3 73.7–87.1
California 151,700 0.9 149,100–154,200 132,153 87.1 0.9 85.7–88.6 152,800 0.9 150,200–155,500 133,497 87.3 0.9 85.8–88.9
Colorado 14,600 2.6 13,900–15,400 12,790 87.5 2.6 83.2–92.2 14,900 2.7 14,100–15,600 13,031 87.7 2.7 83.3–92.5
Connecticut 11,400 3.2 10,600–12,100 10,392 91.5 3.2 86.2–97.6 11,300 3.3 10,600–12,100 10,391 91.7 3.3 86.2–98.0
Delaware 3,800 5.5 3,400–4,200 3,326 87.7 5.5 79.2–98.2 3,900 5.6 3,400–4,300 3,381 87.5 5.7 78.8–98.3
District of Columbia 14,800 2.8 14,000–15,700 13,882 93.5 2.8 88.7–99.0 14,500 2.9 13,700–15,400 13,655 94.0 2.9 88.9–99.6
Florida 129,700 0.9 127,300–132,100 112,068 86.4 0.9 84.8–88.0 130,900 1.0 128,400–133,400 113,398 86.7 1.0 85.0–88.3
Georgia 67,500 1.2 65,900–69,100 56,154 83.2 1.2 81.2–85.3 68,600 1.3 66,800–70,300 57,318 83.6 1.3 81.5–85.8
Hawaii 2,600 6.9 2,300–3,000 2,339 89.4 6.1 78.8–100 2,600 7.1 2,400–3,000 2,351 89.1 6.2 78.2–100
Idahoc 1,600 11.5 1,300–2,000 1,215 74.1 12.2 60.5–95.8 1,700 12.2 1,300–2,100 1,244 74.7 12.9 60.3–98.1
Illinois 40,500 1.7 39,200–41,900 35,248 86.9 1.7 84.1–89.9 40,600 1.8 39,200–42,000 35,390 87.2 1.8 84.3–90.3
Indiana 13,600 2.8 12,900–14,400 11,430 83.8 2.8 79.3–88.7 14,000 3.0 13,200–14,800 11,692 83.6 3.0 79.0–88.7
Iowa 3,400 5.3 3,000–3,700 2,832 84.0 5.3 76.2–93.7 3,400 5.5 3,000–3,800 2,887 84.4 5.6 76.1–94.7
Kansas 3,800 5.6 3,300–4,200 3,104 82.7 5.7 74.6–92.9 3,900 5.6 3,500–4,400 3,264 83.0 5.7 74.7–93.3
Kentucky 9,100 3.3 8,500–9,700 7,456 81.9 3.4 76.9–87.7 9,400 3.5 8,800–10,100 7,761 82.4 3.5 77.2–88.4
Louisiana 25,000 2.2 23,900–26,100 20,964 83.9 2.2 80.5–87.7 25,200 2.3 24,000–26,300 21,131 84.0 2.3 80.4–87.9
Maine 1,800 7.8 1,600–2,100 1,619 88.2 6.8 76.5–100 1,800 8.0 1,600–2,100 1,626 88.4 6.8 76.3–100
Maryland 36,400 1.8 35,200–37,700 32,785 90.0 1.8 87.0–93.2 36,400 1.8 35,200–37,700 32,922 90.3 1.8 87.2–93.6
Massachusetts 22,400 2.1 21,500–23,400 20,526 91.5 2.1 87.8–95.5 22,500 2.2 21,600–23,500 20,671 91.8 2.2 88.0–95.8
Michigan 19,100 2.5 18,100–20,000 16,367 85.9 2.5 81.9–90.3 19,300 2.6 18,400–20,300 16,642 86.0 2.6 81.9–90.6
Minnesota 9,900 3.1 9,300–10,500 8,679 87.7 3.1 82.7–93.3 10,000 3.1 9,400–10,700 8,858 88.1 3.2 83.0–93.9
Mississippid 11,400 3.3 10,700–12,200 9,528 83.4 3.3 78.3–89.2 11,500 3.5 10,700–12,300 9,554 83.1 3.5 77.7–89.2
Missouri 14,500 2.7 13,800–15,300 12,667 87.1 2.7 82.7–92.0 14,600 2.8 13,800–15,400 12,755 87.4 2.8 82.8–92.5
Montana 710 10.3 650–860 652 91.4 6.7 76.0–100 740 10.2 680–890 680 92.0 6.5 76.7–100
Nebraska 2,600 6.3 2,200–2,900 2,184 85.2 6.4 75.9–97.2 2,700 6.4 2,400–3,000 2,287 84.8 6.5 75.4–97.0
Nevada 12,900 2.8 12,200–13,600 10,538 81.8 2.8 77.6–86.6 13,300 3.0 12,600–14,100 10,889 81.6 3.0 77.1–86.6
New Hampshire 1,400 8.4 1,300–1,700 1,275 89.8 6.5 77.1–100 1,400 8.6 1,300–1,700 1,295 90.4 6.4 77.4–100
New Jerseyc 38,700 2.0 37,200–40,200 34,282 88.6 2.0 85.4–92.2 38,700 2.0 37,200–40,200 34,376 88.9 2.0 85.5–92.5
New Mexico 4,300 4.5 3,900–4,700 3,754 87.4 4.6 80.2–95.9 4,400 4.6 4,000–4,800 3,867 87.5 4.7 80.2–96.3
New York 132,800 0.9 130,400–135,200 123,173 92.7 0.9 91.1–94.5 131,600 1.0 129,100–134,100 122,311 92.9 1.0 91.2–94.7
North Carolina 37,900 1.6 36,700–39,100 32,577 86.0 1.6 83.4–88.9 38,300 1.7 37,000–39,500 33,118 86.5 1.7 83.8–89.5
North Dakota 740 14.3 530–950 486 65.6 15.5 51.3–91.3 760 15.0 540–980 515 67.7 16.4 52.4–95.9
Ohio 26,900 2.0 25,800–27,900 22,874 85.1 2.0 81.9–88.5 27,300 2.0 26,200–28,300 23,327 85.6 2.0 82.3–89.1
Oklahoma 7,800 3.9 7,300–8,400 6,321 80.5 3.9 74.9–87.1 8,100 4.0 7,400–8,700 6,550 81.0 4.0 75.1–87.9
Oregon 8,000 3.4 7,500–8,600 7,183 89.6 3.4 84.0–96.0 8,100 3.5 7,500–8,700 7,269 89.6 3.5 83.8–96.3
Pennsylvaniac 39,800 1.7 38,500–41,100 35,721 89.8 1.7 87.0–92.9 39,900 1.7 38,500–41,200 35,860 90.0 1.7 87.0–93.1
Puerto Ricoc,d 17,300 3.1 16,200–18,300 15,556 90.1 3.1 85.0–96.0 17,100 3.2 16,000–18,200 15,496 90.6 3.2 85.3–96.7
Rhode Island 2,900 5.8 2,600–3,200 2,611 91.2 5.1 81.8–100 2,900 6.0 2,600–3,200 2,617 91.0 5.2 81.5–100
South Carolina 20,500 2.4 19,600–21,500 17,236 84.0 2.4 80.2–88.1 20,900 2.5 19,800–21,900 17,568 84.3 2.5 80.4–88.5
South Dakota 800 12.5 640–1,000 636 79.2 11.7 63.6–100 860 12.9 680–1,100 679 78.7 12.1 62.8–100
Tennessee 20,700 2.3 19,700–21,600 17,641 85.3 2.3 81.7–89.3 21,100 2.3 20,100–22,100 18,158 86.0 2.3 82.3–90.2
Texas 113,300 1.0 111,100–115,500 94,185 83.1 1.0 81.6–84.8 115,900 1.0 113,600–118,200 96,755 83.5 1.0 81.9–85.2
Utah 3,700 5.4 3,300–4,100 3,055 83.0 5.4 75.1–92.8 3,900 5.4 3,400–4,300 3,232 83.8 5.5 75.7–93.8
Vermont 750 10.2 690–900 694 92.5 6.3 77.1–100 750 10.4 700–900 697 92.8 6.3 77.0–100
Virginia 26,900 2.1 25,800–28,000 23,253 86.4 2.1 83.1–90.0 27,200 2.1 26,000–28,300 23,563 86.7 2.1 83.3–90.5
Washington 15,800 2.5 15,000–16,600 13,788 87.3 2.6 83.1–91.9 16,100 2.6 15,300–16,900 14,110 87.5 2.6 83.3–92.3
West Virginia 2,600 7.2 2,300–3,000 1,990 75.7 7.3 66.4–88.2 2,800 7.6 2,400–3,200 2,099 75.4 7.8 65.6–88.7
Wisconsin 7,400 3.7 6,900–8,000 6,376 86.0 3.8 80.1–92.8 7,600 3.9 7,000–8,200 6,534 85.7 3.9 79.6–92.7
Wyoming 390 15.5 340–510 340 87.6 9.6 67.2–100 390 16.2 350–520 348 88.5 9.5 67.2–100
  2021a
  Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
  No. RSE 95% CI No.b % RSE 95% CI
Alabama 17,000 2.8 16,100–17,900 14,313 84.3 2.8 79.9–89.2
Alaska 860 12.1 740–1,100 743 86.7 8.8 70.0–100
Arizona 21,400 2.5 20,300–22,400 18,056 84.6 2.5 80.7–88.9
Arkansas 7,800 4.4 7,100–8,400 6,178 79.7 4.5 73.3–87.3
California 154,300 0.9 151,500–157,100 135,306 87.7 0.9 86.1–89.3
Colorado 15,300 2.8 14,400–16,100 13,328 87.3 2.8 82.9–92.3
Connecticut 11,400 3.3 10,600–12,100 10,466 92.0 3.3 86.4–98.5
Delaware 3,900 5.8 3,500–4,400 3,471 87.9 5.9 78.9–99.1
District of Columbia 14,300 3.0 13,500–15,200 13,504 94.2 3.0 89.0–100
Florida 133,000 1.0 130,400–135,600 115,906 87.1 1.0 85.4–88.9
Georgia 70,100 1.4 68,200–72,000 58,899 84.0 1.4 81.8–86.3
Hawaii 2,700 7.3 2,400–3,000 2,369 89.1 6.3 78.0–100
Idahoc 1,700 12.9 1,300–2,100 1,285 75.7 13.4 60.4–100
Illinois 40,500 1.8 39,000–42,000 35,388 87.4 1.8 84.3–90.7
Indiana 14,500 3.0 13,700–15,400 12,208 84.0 3.0 79.3–89.2
Iowa 3,500 5.7 3,200–3,900 3,009 84.8 5.8 76.2–95.5
Kansas 4,100 5.7 3,700–4,600 3,446 83.8 5.8 75.3–94.4
Kentucky 9,800 3.6 9,100–10,400 8,066 82.7 3.7 77.2–89.1
Louisiana 25,300 2.4 24,200–26,500 21,376 84.4 2.4 80.6–88.5
Maine 1,900 8.2 1,700–2,200 1,670 89.0 6.7 76.6–100
Maryland 36,400 1.8 35,000–37,700 32,944 90.6 1.9 87.4–94.0
Massachusetts 22,600 2.2 21,600–23,600 20,793 92.0 2.2 88.1–96.1
Michigan 19,800 2.6 18,800–20,800 17,115 86.4 2.6 82.2–91.1
Minnesota 10,200 3.2 9,600–10,900 9,086 88.7 3.2 83.4–94.7
Mississippid 11,700 3.7 10,900–12,600 9,764 83.2 3.7 77.6–89.6
Missouri 14,800 2.9 14,000–15,700 12,999 87.6 2.9 82.9–92.9
Montana 780 10.1 720–930 717 91.9 6.5 76.7–100
Nebraska 2,800 6.7 2,400–3,100 2,348 84.8 6.8 75.0–97.6
Nevada 13,800 3.1 13,000–14,700 11,336 82.0 3.1 77.3–87.3
New Hampshire 1,500 8.6 1,300–1,700 1,339 90.6 6.3 77.5–100
New Jerseyc 39,000 2.1 37,400–40,600 34,636 88.8 2.1 85.3–92.6
New Mexico 4,600 4.7 4,100–5,000 3,990 87.7 4.8 80.2–96.7
New York 131,100 1.0 128,500–133,600 122,136 93.2 1.0 91.4–95.0
North Carolina 38,900 1.7 37,600–40,200 33,947 87.2 1.7 84.4–90.3
North Dakota 800 16.0 550–1,100 533 66.5 17.8 50.6–97.0
Ohio 27,700 2.1 26,600–28,900 23,842 86.0 2.1 82.6–89.6
Oklahoma 8,400 4.1 7,700–9,100 6,878 81.7 4.2 75.6–88.9
Oregon 8,300 3.7 7,700–8,900 7,433 89.6 3.7 83.6–96.6
Pennsylvaniac 40,100 1.8 38,700–41,500 36,287 90.5 1.8 87.5–93.8
Puerto Ricoc,d 17,100 3.2 16,000–18,200 15,579 91.1 3.3 85.7–97.3
Rhode Island 2,900 6.1 2,700–3,300 2,663 91.6 5.0 81.9–100
South Carolina 21,200 2.6 20,100–22,300 17,914 84.5 2.6 80.5–89.0
South Dakota 910 13.5 710–1,100 708 78.1 12.5 61.7–100
Tennessee 21,400 2.4 20,400–22,400 18,554 86.6 2.4 82.7–90.9
Texas 119,000 1.0 116,500–121,400 99,947 84.0 1.0 82.3–85.8
Utah 4,000 5.6 3,600–4,500 3,409 84.4 5.7 76.0–94.8
Vermont 760 10.4 710–920 714 93.5 6.1 77.6–100
Virginia 27,600 2.2 26,500–28,800 24,143 87.3 2.2 83.8–91.2
Washington 16,500 2.7 15,600–17,300 14,445 87.8 2.7 83.3–92.7
West Virginia 2,900 8.3 2,400–3,300 2,172 76.1 8.5 65.4–90.8
Wisconsin 7,800 4.0 7,200–8,400 6,753 86.2 4.0 79.9–93.5
Wyoming 420 16.2 370–550 368 88.6 9.4 67.2–100

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates for the year 2021 data are preliminary and based on deaths reported to CDC as of December 2022. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥ 13 years at diagnosis.

Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤ 1,000 to reflect the uncertainty.

a Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017‒2021 for more information.
b Reported to the National HIV Surveillance System.
c Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.
d Estimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

  2017 2018
  Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
  No. RSE 95% CI No.b % RSE 95% CI No. RSE 95% CI No.b % RSE 95% CI
Arizona
Maricopa County 13,000 2.7 12,300–13,600 10,672 82.4 2.7 78.2 13,400 2.8 12,700–14,100 11,101 82.8 2.8 78.6–87.6
California
Alameda County 6,700 4.0 6,200–7,200 5,813 86.8 4.0 80.5 6,900 4.0 6,300–7,400 5,984 87.3 4.0 81.0–94.7
Los Angeles County 54,300 1.4 52,800–55,800 47,840 88.1 1.4 85.7 54,900 1.4 53,400–56,400 48,646 88.6 1.4 86.2–91.1
Orange County 8,100 3.6 7,600–8,700 6,719 82.5 3.6 77.0 8,200 3.7 7,600–8,800 6,824 82.8 3.7 77.3–89.3
Riverside County 9,600 2.6 9,100–10,100 8,455 88.4 2.6 84.1 10,100 2.6 9,600–10,600 9,000 88.8 2.6 84.6–93.5
Sacramento County 5,000 4.3 4,500–5,400 4,173 84.1 4.3 77.5 5,100 4.3 4,700–5,600 4,303 83.8 4.4 77.3–91.6
San Bernardino County 5,300 4.3 4,800–5,700 4,092 77.4 4.3 71.3 5,600 4.2 5,200–6,100 4,422 78.7 4.3 72.7–85.8
San Diego County 14,900 2.6 14,100–15,600 12,848 86.4 2.6 82.2 15,100 2.6 14,300–15,900 13,032 86.3 2.6 82.1–90.9
San Francisco County 12,800 3.4 12,300–13,700 12,279 95.6 2.8 89.7 12,600 3.5 12,100–13,400 12,093 96.2 2.7 90.0–100
District of Columbia 15,100 2.7 14,300–15,900 14,039 93.0 2.7 88.4 14,900 2.7 14,100–15,700 13,917 93.2 2.7 88.5–98.5
Florida
Broward County 21,400 2.1 20,600–22,300 19,045 88.8 2.1 85.3 21,700 2.1 20,800–22,600 19,334 89.2 2.1 85.6–93.1
Duval County 7,100 3.9 6,500–7,600 5,834 82.4 3.9 76.6 7,200 3.9 6,700–7,800 6,018 83.1 3.9 77.2–90.0
Hillsborough County 7,900 3.6 7,300–8,500 6,628 83.8 3.7 78.2 8,000 3.7 7,500–8,600 6,775 84.2 3.7 78.5–90.8
Miami-Dade County 29,500 2.0 28,400–30,700 25,649 86.8 2.0 83.5 29,800 2.0 28,600–31,000 25,960 87.1 2.0 83.8–90.7
Orange County 10,100 3.2 9,500–10,700 8,298 82.3 3.2 77.5 10,300 3.2 9,700–11,000 8,555 83.0 3.2 78.1–88.6
Palm Beach County 8,900 3.6 8,300–9,600 7,724 86.6 3.6 80.9 9,000 3.7 8,300–9,600 7,779 86.8 3.7 81.0–93.5
Pinellas County 5,200 4.3 4,800–5,700 4,488 85.8 4.3 79.2 5,200 4.4 4,800–5,700 4,524 86.5 4.4 79.7–94.7
Georgia
Cobb County 3,700 4.6 3,400–4,000 2,994 80.9 4.7 74.1 3,900 4.7 3,500–4,200 3,162 81.7 4.7 74.8–89.9
DeKalb County 9,600 3.1 9,000–10,200 8,108 84.1 3.2 79.3 10,000 3.1 9,400–10,600 8,455 84.4 3.2 79.5–89.9
Fulton County 16,800 2.4 16,000–17,600 14,230 84.9 2.4 81.1 17,600 2.4 16,800–18,400 15,043 85.5 2.4 81.7–89.6
Gwinnett County 3,400 4.5 3,100–3,700 2,716 79.4 4.5 73.0 3,500 4.6 3,200–3,900 2,843 80.2 4.6 73.6–88.1
Illinois
Cook County 28,300 2.0 27,200–29,400 24,537 86.6 2.0 83.3 28,500 2.0 27,400–29,700 24,833 87.1 2.0 83.7–90.7
Indiana
Marion County 5,300 4.2 4,900–5,700 4,475 84.6 4.2 78.1 5,400 4.2 5,000–5,900 4,605 84.7 4.3 78.2–92.3
Louisiana
East Baton Rouge Parish 4,500 4.8 4,000–4,900 3,788 84.9 4.8 77.6 4,500 4.9 4,100–5,000 3,852 85.1 4.9 77.7–94.1
Orleans Parish 5,300 5.1 4,800–5,900 4,729 88.5 5.1 80.5 5,400 5.1 4,900–5,900 4,822 89.1 5.1 81.1–99.0
Maryland
Baltimore City 11,800 3.3 11,000–12,500 10,855 92.2 3.3 86.5 10,900 3.6 10,200–11,700 10,034 91.8 3.7 85.6–98.8
Montgomery County 4,200 4.7 3,900–4,600 3,770 88.8 4.8 81.2 4,300 4.8 3,900–4,700 3,829 89.6 4.9 81.9–98.9
Prince George’s County 8,800 3.3 8,200–9,400 7,579 86.0 3.3 80.9 9,000 3.3 8,400–9,600 7,839 86.9 3.3 81.7–92.9
Massachusetts
Suffolk County 6,100 4.2 5,700–6,600 5,671 93.1 3.8 86.0 6,000 4.3 5,600–6,500 5,620 93.4 3.8 86.2–100
Michigan
Wayne County 7,500 4.1 6,900–8,100 6,357 84.8 4.2 78.4 7,800 4.1 7,100–8,400 6,656 85.8 4.1 79.4–93.3
Nevada
Clark County 9,800 3.0 9,200–10,400 7,935 80.9 3.0 76.4 10,400 3.0 9,800–11,000 8,448 81.3 3.0 76.8–86.3
New Jersey
Essex Countyc 9,900 3.9 9,100–10,600 8,879 89.7 3.9 83.4 9,800 4.0 9,100–10,600 8,843 90.1 4.0 83.6–97.7
Hudson Countyc 5,400 5.1 4,900–6,000 4,752 87.2 5.2 79.3 5,500 5.2 4,900–6,000 4,768 87.5 5.3 79.4–97.4
New York
Bronx County 28,300 1.8 27,300–29,300 26,493 93.6 1.8 90.5 28,400 1.8 27,400–29,400 26,690 93.9 1.8 90.7–97.3
Kings County 27,700 2.0 26,600–28,800 25,567 92.4 2.0 88.9 27,700 2.0 26,600–28,800 25,727 92.8 2.0 89.2–96.6
New York County 28,200 2.1 27,000–29,300 26,536 94.2 2.1 90.5 28,100 2.1 26,900–29,300 26,527 94.4 2.1 90.6–98.6
Queens County 16,900 2.5 16,100–17,800 15,303 90.4 2.5 86.2 17,100 2.5 16,200–17,900 15,528 91.0 2.5 86.8–95.7
North Carolina
Mecklenburg County 6,500 3.8 6,000–7,000 5,598 85.9 3.8 80.0 6,700 3.7 6,200–7,200 5,800 86.3 3.8 80.4–93.1
Ohio
Cuyahoga County 5,300 4.2 4,900–5,700 4,557 86.0 4.2 79.5 5,400 4.2 4,900–5,800 4,670 86.6 4.3 80.0–94.5
Franklin County 5,500 4.1 5,100–6,000 4,704 85.0 4.1 78.7 5,600 4.1 5,100–6,000 4,758 85.1 4.2 78.7–92.6
Hamilton County 3,600 5.1 3,200–3,900 2,856 80.1 5.2 72.7 3,600 5.3 3,200–3,900 2,889 81.2 5.4 73.5–90.7
Pennsylvania
Philadelphia County 18,300 2.4 17,400–19,100 16,746 91.7 2.4 87.6 18,200 2.4 17,300–19,000 16,688 91.8 2.4 87.7–96.4
Puerto Rico
San Juan Municipioc 3,600 7.1 3,200–4,100 3,207 89.0 6.3 78.0 3,600 7.2 3,200–4,100 3,248 90.0 6.0 78.8–100
Tennessee
Shelby County 7,100 3.8 6,500–7,600 6,031 85.2 3.9 79.2 7,300 3.8 6,800–7,800 6,291 86.2 3.8 80.2–93.1
Texas
Bexar County 7,300 3.6 6,800–7,900 6,074 82.7 3.7 77.2 7,500 3.7 7,000–8,100 6,253 83.2 3.7 77.6–89.7
Dallas County 20,800 2.2 19,900–21,700 17,319 83.2 2.2 79.8 21,500 2.2 20,600–22,400 17,966 83.6 2.2 80.2–87.3
Harris County 29,700 1.9 28,600–30,700 24,623 83.0 1.9 80.1 30,400 1.9 29,200–31,500 25,422 83.7 1.9 80.7–86.9
Tarrant County 6,600 3.7 6,100–7,100 5,405 81.7 3.7 76.1 6,900 3.7 6,300–7,400 5,636 82.3 3.8 76.6–88.8
Travis County 5,600 4.2 5,200–6,100 4,693 83.4 4.2 77.1 5,900 4.2 5,400–6,300 4,883 83.3 4.2 77.0–90.7
Washington
King County 7,700 3.7 7,200–8,300 6,745 87.1 3.7 81.2 7,800 3.8 7,200–8,400 6,805 87.5 3.8 81.4–94.5
  2019 2020 (COVID-19 pandemic)a
  Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
  No. RSE 95% CI No.b % RSE 95% CI No. RSE 95% CI No.b % RSE 95% CI
Arizona
Maricopa County 13,900 2.8 13,100–14,600 11,561 83.4 2.8 79.0–88.2 14,200 2.9 13,400–15,000 11,926 84.0 2.9 79.5–89.1
California
Alameda County 6,900 4.1 6,300–7,400 6,038 87.6 4.1 81.1–95.2 6,800 4.3 6,200–7,400 5,965 87.9 4.3 81.1–95.9
Los Angeles County 55,500 1.4 54,000–57,100 49,420 89.0 1.4 86.5–91.5 55,700 1.5 54,100–57,300 49,814 89.4 1.5 86.9–92.0
Orange County 8,300 3.7 7,700–8,900 6,917 83.2 3.8 77.5–89.8 8,400 3.8 7,800–9,000 7,034 83.6 3.9 77.8–90.5
Riverside County 10,500 2.6 10,000–11,000 9,367 89.3 2.6 85.0–94.0 10,800 2.6 10,300–11,400 9,709 89.5 2.6 85.1–94.4
Sacramento County 5,300 4.4 4,800–5,700 4,412 83.5 4.4 76.9–91.3 5,400 4.5 4,900–5,900 4,534 83.8 4.5 77.0–91.9
San Bernardino County 5,900 4.3 5,400–6,400 4,692 79.4 4.3 73.3–86.7 6,000 4.5 5,500–6,600 4,803 79.7 4.5 73.3–87.4
San Diego County 15,300 2.7 14,500–16,100 13,176 86.3 2.7 82.1–91.1 15,400 2.7 14,600–16,200 13,299 86.4 2.7 82.1–91.3
San Francisco County 12,400 3.6 12,000–13,200 11,972 96.9 2.5 90.5–100 12,100 3.7 11,800–13,000 11,781 97.2 2.5 90.6–100
District of Columbia 14,800 2.8 14,000–15,700 13,882 93.5 2.8 88.7–99.0 14,500 2.9 13,700–15,400 13,655 94.0 2.9 88.9–99.6
Florida
Broward County 22,000 2.2 21,000–22,900 19,650 89.4 2.2 85.7–93.4 22,100 2.2 21,100–23,100 19,811 89.6 2.2 85.8–93.7
Duval County 7,300 4.0 6,700–7,900 6,152 84.1 4.0 78.0–91.2 7,400 4.1 6,800–8,000 6,266 84.4 4.1 78.1–91.8
Hillsborough County 8,200 3.7 7,600–8,800 6,989 84.8 3.7 79.1–91.4 8,400 3.8 7,800–9,000 7,176 85.2 3.8 79.3–92.1
Miami-Dade County 29,900 2.1 28,700–31,200 26,186 87.4 2.1 84.0–91.2 30,000 2.2 28,700–31,200 26,269 87.6 2.2 84.1–91.5
Orange County 10,500 3.3 9,800–11,200 8,759 83.3 3.3 78.2–89.0 10,600 3.4 9,900–11,400 8,892 83.5 3.5 78.2–89.5
Palm Beach County 9,100 3.7 8,400–9,700 7,864 86.8 3.7 80.9–93.6 9,200 3.8 8,500–9,900 7,925 86.3 3.8 80.3–93.3
Pinellas County 5,400 4.4 4,900–5,900 4,731 87.6 4.4 80.7–95.7 5,500 4.5 5,000–6,000 4,836 88.3 4.5 81.1–96.8
Georgia
Cobb County 4,000 4.8 3,700–4,400 3,324 82.1 4.8 75.1–90.6 4,200 5.0 3,800–4,600 3,481 82.5 5.0 75.2–91.4
DeKalb County 10,400 3.2 9,700–11,000 8,823 85.1 3.2 80.1–90.7 10,500 3.3 9,800–11,200 8,964 85.5 3.3 80.3–91.4
Fulton County 18,100 2.4 17,300–19,000 15,572 85.9 2.4 82.1–90.1 18,500 2.5 17,600–19,400 15,937 86.1 2.5 82.2–90.5
Gwinnett County 3,700 4.7 3,400–4,100 3,039 81.5 4.8 74.6–89.9 3,800 5.0 3,400–4,200 3,177 83.2 5.0 75.8–92.2
Illinois
Cook County 29,100 2.0 27,900–30,200 25,486 87.6 2.0 84.3–91.3 29,200 2.1 28,000–30,400 25,639 87.8 2.1 84.3–91.6
Indiana
Marion County 5,500 4.4 5,000–5,900 4,605 84.2 4.4 77.6–92.2 5,600 4.5 5,100–6,100 4,726 84.2 4.6 77.3–92.4
Louisiana
East Baton Rouge Parish 4,600 5.0 4,100–5,000 3,886 85.0 5.1 77.4–94.3 4,700 5.0 4,200–5,200 4,051 86.0 5.1 78.3–95.4
Orleans Parish 5,500 5.1 4,900–6,000 4,913 89.8 5.2 81.6–99.8 5,400 5.3 4,900–6,000 4,886 89.9 5.2 81.5–100
Maryland
Baltimore City 10,900 3.7 10,100–11,700 10,025 92.3 3.7 86.0–99.5 10,500 3.9 9,700–11,300 9,725 92.2 3.9 85.7–99.8
Montgomery County 4,300 4.9 3,900–4,700 3,868 90.4 5.0 82.4–100 4,200 5.1 3,800–4,600 3,825 90.7 4.9 82.4–100
Prince George’s County 9,100 3.4 8,500–9,700 7,929 87.5 3.4 82.1–93.6 9,000 3.5 8,400–9,600 7,973 88.3 3.5 82.7–94.7
Massachusetts
Suffolk County 6,000 4.3 5,600–6,500 5,624 93.6 3.7 86.3–100 6,000 4.4 5,600–6,500 5,632 93.6 3.8 86.2–100
Michigan
Wayne County 8,000 4.1 7,300–8,600 6,868 86.3 4.1 79.9–93.8 8,000 4.2 7,400–8,700 6,940 86.3 4.2 79.7–94.1
Nevada
Clark County 10,900 3.0 10,200–11,500 8,893 81.8 3.0 77.2–86.9 11,300 3.2 10,600–12,000 9,252 81.5 3.2 76.8–86.9
New Jersey
Essex Countyc 9,800 4.0 9,000–10,600 8,853 90.4 4.1 83.8–98.2 9,700 4.2 8,900–10,500 8,768 90.6 4.2 83.7–98.7
Hudson Countyc 5,500 5.3 4,900–6,000 4,808 88.2 5.4 79.9–98.4 5,400 5.5 4,800–6,000 4,799 88.5 5.6 79.9–99.3
New York
Bronx County 28,700 1.8 27,700–29,700 27,121 94.4 1.8 91.2–97.8 28,400 1.8 27,400–29,400 26,797 94.3 1.8 91.0–97.9
Kings County 27,700 2.1 26,600–28,800 25,730 93.0 2.1 89.4–96.9 27,400 2.1 26,200–28,500 25,541 93.3 2.1 89.6–97.4
New York County 27,800 2.2 26,600–29,000 26,340 94.6 2.2 90.7–98.8 27,400 2.2 26,200–28,600 25,945 94.7 2.2 90.7–99.0
Queens County 17,200 2.5 16,300–18,000 15,728 91.7 2.5 87.3–96.5 17,100 2.6 16,200–17,900 15,716 92.1 2.6 87.6–97.0
North Carolina
Mecklenburg County 7,000 3.8 6,500–7,500 6,023 86.4 3.8 80.5–93.3 7,100 3.9 6,500–7,600 6,127 86.7 3.9 80.5–93.8
Ohio
Cuyahoga County 5,400 4.3 5,000–5,900 4,752 87.3 4.3 80.5–95.3 5,500 4.4 5,000–6,000 4,850 87.7 4.4 80.8–96.0
Franklin County 5,800 4.1 5,300–6,300 4,991 85.8 4.2 79.3–93.4 5,900 4.2 5,400–6,400 5,132 86.5 4.3 79.9–94.3
Hamilton County 3,600 5.4 3,300–4,000 3,024 83.0 5.5 75.0–92.8 3,700 5.6 3,300–4,100 3,083 83.4 5.6 75.2–93.6
Pennsylvania
Philadelphia County 18,300 2.4 17,400–19,200 16,848 92.1 2.4 87.9–96.7 18,000 2.5 17,100–18,900 16,651 92.4 2.5 88.0–97.2
Puerto Rico
San Juan Municipioc 3,700 7.2 3,300–4,200 3,309 90.4 5.8 79.3–100 3,700 7.2 3,400–4,200 3,392 91.3 5.6 80.0–100
Tennessee
Shelby County 7,400 3.9 6,800–7,900 6,332 86.0 3.9 79.9–93.2 7,200 4.1 6,600–7,800 6,246 86.7 4.1 80.3–94.4
Texas
Bexar County 7,800 3.7 7,200–8,400 6,500 83.3 3.8 77.6–89.9 8,100 3.9 7,500–8,700 6,727 83.3 3.9 77.4–90.2
Dallas County 21,900 2.2 21,000–22,900 18,499 84.4 2.2 80.9–88.2 22,300 2.3 21,300–23,300 18,953 84.9 2.3 81.3–88.8
Harris County 31,200 1.9 20,100–32,400 26,367 84.4 1.9 81.3–87.7 31,800 2.0 30,500–33,000 26,897 84.7 2.0 81.5–88.1
Tarrant County 7,200 3.8 6,600–7,700 5,882 82.1 3.8 76.4–88.7 7,400 3.9 6,900–8,000 6,144 82.6 4.0 76.6–89.5
Travis County 6,000 4.2 5,500–6,500 5,024 83.7 4.3 77.3–91.2 6,100 4.3 5,600–6,600 5,138 84.3 4.4 77.7–92.1
Washington
King County 7,900 3.9 7,300–8,500 6,969 88.0 3.9 81.8–95.2 8,000 4.0 7,300–8,600 7,024 88.1 4.0 81.7–95.6
  2021a
  Persons living with diagnosed or undiagnosed HIV infection Persons living with diagnosed HIV infection
  No. RSE 95% CI No.b % RSE 95% CI
Arizona
Maricopa County 14,500 3.0 13,700–15,400 12,286 84.6 3.0 79.8–89.9
California
Alameda County 6,800 4.4 6,200–7,300 5,950 88.0 4.5 81.0–96.4
Los Angeles County 55,800 1.5 54,200–57,500 50,182 89.9 1.5 87.3–92.7
Orange County 8,500 3.9 7,900–9,200 7,181 84.2 4.0 78.1–91.3
Riverside County 11,200 2.7 10,600–11,800 10,089 90.0 2.7 85.5–94.9
Sacramento County 5,400 4.6 4,900–5,900 4,610 84.8 4.7 77.7–93.3
San Bernardino County 6,200 4.6 5,600–6,800 5,009 80.6 4.7 73.9–88.7
San Diego County 15,600 2.8 14,700–16,400 13,442 86.3 2.8 81.8–91.3
San Francisco County 11,900 3.8 11,600–12,800 11,601 97.5 2.4 90.7–100
District of Columbia 14,300 3.0 13,500–15,200 13,504 94.2 3.0 89.0–100
Florida
Broward County 22,400 2.3 21,400–23,400 20,137 90.0 2.3 86.1–94.2
Duval County 7,500 4.2 6,900–8,100 6,413 85.3 4.3 78.8–93.0
Hillsborough County 8,500 3.9 7,900–9,200 7,379 86.7 3.9 80.6–93.8
Miami-Dade County 30,500 2.2 29,200–31,800 26,875 88.1 2.2 84.4–92.0
Orange County 11,100 3.5 10,300–11,800 9,252 83.7 3.5 78.3–89.9
Palm Beach County 9,300 3.9 8,500–10,000 8,034 86.8 3.9 80.7–94.0
Pinellas County 5,500 4.6 5,000–6,000 4,895 88.9 4.6 81.5–97.7
Georgia
Cobb County 4,300 5.1 3,900–4,800 3,623 83.8 5.2 76.1–93.1
DeKalb County 10,600 3.5 9,800–11,300 9,064 85.8 3.5 80.4–92.0
Fulton County 18,900 2.5 17,900–19,800 16,290 86.3 2.6 82.2–90.9
Gwinnett County 3,900 5.2 3,500–4,300 3,315 84.6 5.3 76.7–94.3
Illinois
Cook County 29,000 2.2 27,800–30,300 25,493 87.9 2.2 84.3–91.9
Indiana
Marion County 5,800 4.6 5,300–6,300 4,927 84.8 4.7 77.7–93.2
Louisiana
East Baton Rouge Parish 4,700 5.2 4,200–5,200 4,086 86.7 5.2 78.7–96.5
Orleans Parish 5,400 5.5 4,800–5,900 4,822 90.0 5.3 81.3–100
Maryland
Baltimore City 10,900 3.8 10,100–11,700 10,109 92.5 3.8 86.1–100
Montgomery County 4,300 5.2 3,900–4,700 3,889 91.3 4.8 82.9–100
Prince George’s County 9,000 3.6 8,400–9,600 7,959 88.5 3.6 82.7–95.3
Massachusetts
Suffolk County 6,000 4.5 5,600–6,500 5,594 93.6 3.8 86.1–100
Michigan
Wayne County 8,300 4.2 7,600–8,900 7,180 87.0 4.3 80.3–94.9
Nevada
Clark County 11,700 3.3 11,000–12,500 9,630 82.0 3.3 77.0–87.7
New Jersey
Essex Countyc 9,700 4.3 8,800–10,500 8,723 90.2 4.4 83.2–98.6
Hudson Countyc 5,500 5.5 4,900–6,100 4,884 88.7 5.6 80.0–99.5
New York
Bronx County 28,100 1.9 27,100–29,200 26,554 94.4 1.9 91.0–98.0
Kings County 27,300 2.2 26,100–28,400 25,538 93.6 2.2 89.8–97.7
New York County 27,200 2.3 26,000–28,400 25,805 94.8 2.3 90.8–99.3
Queens County 17,200 2.6 16,300–18,100 15,909 92.5 2.6 88.0–97.6
North Carolina
Mecklenburg County 7,100 4.0 6,600–7,700 6,227 87.6 4.0 81.2–95.0
Ohio
Cuyahoga County 5,600 4.6 5,100–6,100 4,923 88.0 4.6 80.8–96.6
Franklin County 6,000 4.4 5,500–6,500 5,214 87.1 4.4 80.2–95.3
Hamilton County 3,700 5.7 3,300–4,100 3,135 84.1 5.8 75.5–94.7
Pennsylvania
Philadelphia County 17,900 2.6 17,000–18,800 16,546 92.6 2.6 88.1–97.6
Puerto Rico
San Juan Municipioc 3,900 6.9 3,600–4,500 3,622 92.3 5.2 81.3–100
Tennessee
Shelby County 7,400 4.2 6,800–8,000 6,482 87.8 4.2 81.2–95.6
Texas
Bexar County 8,200 4.0 7,600–8,900 6,875 83.7 4.1 77.5–90.9
Dallas County 22,900 2.3 21,800–23,900 19,505 85.3 2.4 81.6–89.4
Harris County 32,400 2.0 33,700–27,585 27,585 85.2 2.0 81.9–88.7
Tarrant County 7,700 4.1 8,300–6,346 6,346 82.7 4.1 76.5–89.9
Travis County 6,200 4.5 6,700–5,229 5,229 84.9 4.6 78.0–93.1
Washington
King County 8,100 4.1 8,700–7,127 7,127 88.4 4.1 81.8–96.2

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates for the year 2021 data are preliminary and based on deaths reported to CDC as of December 2022. Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥ 13 years at diagnosis.

Estimates rounded to the nearest 100 for estimates > 1,000 and to the nearest 10 for estimates ≤ 1,000 to reflect the uncertainty.

a Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017‒2021 for more information.
b Reported to the National HIV Surveillance System.
c Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

2017 2018 2019 2020 (COVID-19 pandemic)a 2021 2022 (preliminary)b
No. No. No. No. No. No.
Gender
Male 30,398 29,563 28,779 24,148 28,283 26,095
Female 7,229 7,008 6,873 5,387 6,522 6,018
Transgender womanc 651 661 692 676 811 639
Transgender manc 32 48 45 41 56 42
Additional gender identityd 18 19 32 23 44 52
Age at diagnosis (yr)
13–24 8,297 7,865 7,660 6,125 6,927 5,961
25–34 13,400 13,346 13,027 11,279 13,081 12,211
35–44 7,235 7,150 7,048 5,874 7,543 7,289
45–54 5,563 5,194 4,874 3,872 4,442 3,991
≥ 55 3,833 3,744 3,812 3,125 3,723 3,394
Race/ethnicity
American Indian/Alaska Native 193 170 193 189 223 186
Asian 911 844 722 610 737 707
Black/African American 16,107 15,593 15,296 12,643 14,522 13,214
Hispanic/Latinoe 9,995 9,921 9,851 8,037 10,059 9,835
Native Hawaiian/other Pacific Islander 46 57 59 63 76 75
White 9,543 9,323 8,985 7,732 9,058 8,190
Multiracial 1,533 1,391 1,315 1,001 1,041 639
Transmission categoryf
Male-to-male sexual contactg 25,345 24,464 23,870 20,460 23,855 22,362
Injection drug useh
Male 1,291 1,376 1,362 1,170 1,415 1,231
Female 1,109 1,117 1,182 895 1,075 1,002
Male-to-male sexual contactg and injection drug useh 1,517 1,531 1,581 1,185 1,373 1,055
Heterosexual contacti
Male 2,882 2,839 2,643 2,006 2,460 2,097
Female 6,106 5,892 5,695 4,494 5,456 4,991
Region of residence
Northeast 5,988 5,552 5,317 4,241 4,988 4,221
Midwest 5,099 4,941 4,767 4,106 4,815 4,284
South 19,645 19,225 18,950 15,537 18,703 17,957
West 7,596 7,581 7,387 6,391 7,210 6,384
Totalj 38,328 37,299 36,421 30,275 35,716 32,846

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through December 2022.

a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
b Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

  2017 2018 2019 2020 (COVID-19 pandemic)a 2021 2022 (preliminary)b
  No. No. No. No. No. No.
Gender
Male 30,765 29,941 29,118 24,409 28,620 26,374
Female 7,323 7,089 6,956 5,433 6,604 6,077
Transgender womanc 653 665 694 679 812 640
Transgender manc 32 48 45 41 56 42
Additional gender identityd 18 19 32 23 44 52
Age at diagnosis (yr)
13–24 8,376 7,948 7,724 6,177 6,987 6,006
25–34 13,523 13,482 13,145 11,361 13,204 12,326
35–44 7,323 7,227 7,126 5,940 7,634 7,354
45–54 5,655 5,289 4,943 3,926 4,519 4,046
≥ 55 3,914 3,816 3,907 3,181 3,792 3,453
Race/ethnicity
American Indian/Alaska Native 193 170 193 189 223 186
Asian 914 848 729 610 738 707
Black/African American 16,112 15,605 15,304 12,650 14,528 13,218
Hispanic/Latinoe 10,441 10,359 10,250 8,338 10,467 10,165
Native Hawaiian/other Pacific Islander 49 59 63 64 76 75
White 9,547 9,329 8,991 7,733 9,063 8,195
Multiracial 1,535 1,392 1,315 1,001 1,041 639
Transmission categoryf
Male-to-male sexual contactg 25,587 24,742 24,110 20,660 24,107 22,565
Injection drug useh
Male 1,325 1,401 1,385 1,189 1,436 1,255
Female 1,118 1,120 1,188 898 1,077 1,007
Male-to-male sexual contactg and injection drug useh 1,529 1,542 1,595 1,190 1,375 1,059
Heterosexual contacti
Male 2,963 2,906 2,709 2,046 2,523 2,146
Female 6,190 5,970 5,773 4,536 5,536 5,045
Region of residence
Northeast 5,988 5,552 5,317 4,241 4,988 4,221
Midwest 5,099 4,941 4,767 4,106 4,815 4,284
South 19,645 19,225 18,950 15,537 18,703 17,957
West 7,596 7,581 7,387 6,391 7,210 6,384
U.S. dependent areas 463 463 424 310 420 339
Totalj 38,791 37,762 36,845 30,585 36,136 33,185

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through December 2022.

a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
b Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

2017 2018 2019 2020 (COVID-19 pandemic)a 2021 2022 (preliminary)b
Area of residence No. No. No. No. No. No.
Alabama 647 606 635 590 625 402
Alaska 29 23 27 29 30 31
Arizona 721 752 748 657 781 703
Arkansas 285 283 289 245 338 330
California 4,856 4,764 4,508 4,010 4,399 3,702
Colorado 433 400 463 327 406 387
Connecticut 274 258 213 171 233 188
Delaware 125 92 93 92 81 123
District of Columbia 315 278 248 194 195 190
Florida 4,546 4,352 4,150 3,230 4,072 4,815
Georgia 2,607 2,505 2,408 1,974 2,371 2,351
Hawaii 76 72 63 50 65 47
Idaho 45 36 34 35 54 34
Illinois 1,382 1,379 1,281 1,081 1,195 998
Indiana 514 514 484 430 528 557
Iowa 125 114 101 100 124 117
Kansas 119 155 132 140 154 124
Kentucky 368 377 326 300 390 376
Louisiana 987 954 879 718 899 872
Maine 29 31 30 16 31 33
Maryland 1,014 994 914 709 749 679
Massachusetts 600 645 537 430 440 268
Michigan 771 718 675 517 633 597
Minnesota 278 288 276 230 297 251
Mississippi 431 475 469 404 419 362
Missouri 505 449 488 369 549 484
Montana 29 24 25 14 22 10
Nebraska 87 77 80 73 105 84
Nevada 497 498 517 397 501 502
New Hampshire 32 38 31 32 32 28
New Jersey 1,110 1,015 1,084 799 1,143 882
New Mexico 148 155 176 129 149 73
New York 2,741 2,454 2,345 1,975 2,116 1,936
North Carolina 1,289 1,180 1,367 1,079 1,390 1,274
North Dakota 39 35 40 37 37 5
Ohio 980 977 965 882 909 772
Oklahoma 302 278 346 342 387 267
Oregon 203 227 198 179 202 234
Pennsylvania 1,097 1,018 994 753 913 834
Rhode Island 85 75 72 52 68 48
South Carolina 704 726 721 660 652 596
South Dakota 41 29 34 34 31 32
Tennessee 720 740 768 646 831 798
Texas 4,363 4,429 4,350 3,596 4,363 3,589
Utah 116 121 135 133 133 126
Vermont 20 18 11 13 12 4
Virginia 864 863 832 618 792 800
Washington 433 497 480 417 461 525
West Virginia 78 93 155 140 149 133
Wisconsin 258 206 211 213 253 263
Wyoming 10 12 13 14 7 10
Subtotal 38,328 37,299 36,421 30,275 35,716 32,846
U.S. dependent areas
American Samoa 0 0 0 0 0 0
Guam 6 7 11 1 0 0
Northern Mariana Islands 1 1 2 0 0 0
Puerto Rico 447 437 396 300 410 328
Republic of Palau 0 0 0 0 0 0
U.S. Virgin Islands 9 18 15 9 10 11
Subtotal 463 463 424 310 420 339
Total 38,791 37,762 36,845 30,585 36,136 33,185

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through December 2022.

a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
b Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

  2017 2018 2019 2020 (COVID-19 pandemic)a 2021 2022 (preliminary)b
  No. No. No. No. No. No.
Arizona
Maricopa County 492 528 507 471 518 472
California
Alameda County 204 201 219 159 185 193
Los Angeles County 1,749 1,706 1,545 1,403 1,486 1,160
Orange County 314 287 245 264 266 235
Riverside County 275 263 266 237 258 242
Sacramento County 183 178 164 154 175 108
San Bernardino County 257 262 296 265 301 218
San Diego County 415 385 403 328 369 181
San Francisco County 242 238 210 154 185 201
District of Columbia 315 278 248 194 195 190
Florida
Broward County 671 583 555 424 570 648
Duval County 295 267 279 231 280 292
Hillsborough County 300 284 256 237 294 309
Miami-Dade County 1,140 1,100 1,056 736 937 1,212
Orange County 465 441 442 358 416 452
Palm Beach County 285 272 222 201 273 341
Pinellas County 165 174 179 149 122 141
Georgia
Cobb County 156 157 178 135 152 151
DeKalb County 369 359 341 264 342 369
Fulton County 618 601 531 474 525 556
Gwinnett County 177 148 208 144 165 141
Illinois
Cook County 989 989 902 759 843 644
Indiana
Marion County 226 205 204 169 216 218
Louisiana
East Baton Rouge Parish 163 177 155 124 141 127
Orleans Parish 180 176 159 102 145 138
Maryland
Baltimore City 236 233 196 173 156 133
Montgomery County 162 126 131 79 96 104
Prince George’s County 301 305 279 218 229 231
Massachusetts
Suffolk County 164 147 133 131 132 72
Michigan
Wayne County 322 300 289 227 256 236
Nevada
Clark County 449 443 450 346 445 457
New Jersey
Essex County 309 259 229 200 266 183
Hudson County 160 164 147 127 149 144
New York
Bronx County 500 460 504 345 416 345
Kings County 635 550 474 443 441 405
New York County 398 374 339 298 317 289
Queens County 434 417 355 322 333 315
North Carolina
Mecklenburg County 267 237 269 208 278 251
Ohio
Cuyahoga County 148 151 159 183 164 124
Franklin County 223 194 215 206 187 146
Hamilton County 187 183 172 132 122 85
Pennsylvania
Philadelphia County 509 439 445 305 360 307
Puerto Rico
San Juan Municipio 112 104 89 77 99 95
Tennessee
Shelby County 259 290 260 234 294 320
Texas
Bexar County 348 322 332 285 328 260
Dallas County 824 800 747 663 798 769
Harris County 1,103 1,207 1,222 934 1,161 1,102
Tarrant County 303 280 314 294 302 277
Travis County 212 189 178 164 225 209
Washington
King County 212 287 242 199 218 285

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through December 2022.

a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
b Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

2021 2022 (January-September, preliminary)a
Total diagnoses ≥ 1 CD4 or VL tests No CD4 or VL test Total diagnoses ≥ 1 CD4 or VL tests No CD4 or VL test
No. No. % No. % No. No. % No. %
Gender
Male 26,654 21,833 81.9 4,821 18.1 20,566 17,079 83.0 3,487 17.0
Female 6,069 4,961 81.7 1,108 18.3 4,707 3,835 81.5 872 18.5
Transgender womanb 785 654 83.3 131 16.7 535 452 84.5 83 15.5
Transgender manb 55 51 92.7 4 7.3 32 31 96.9 1 3.1
Additional gender identityc 43 36 83.7 7 16.3 39 38 97.4 1 2.6
Age at diagnosis (yr)
13-24 6,561 5,263 80.2 1,298 19.8 4,810 3,953 82.2 857 17.8
25-34 12,337 10,074 81.7 2,263 18.3 9,609 7,959 82.8 1,650 17.2
35-44 7,087 5,824 82.2 1,263 17.8 5,727 4,772 83.3 955 16.7
45-54 4,153 3,462 83.4 691 16.6 3,142 2,597 82.7 545 17.3
>55 3,468 2,912 84.0 556 16.0 2,591 2,154 83.1 437 16.9
Race/ethnicity
American Indian/Alaska Native 220 182 82.7 38 17.3 156 122 78.2 34 21.8
Asian 699 608 87.0 91 13.0 571 510 89.3 61 10.7
Black/African American 13,650 10,889 79.8 2,761 20.2 10,422 8,316 79.8 2,106 20.2
Hispanic/Latinod 9,416 7,958 84.5 1,458 15.5 7,730 6,695 86.6 1,035 13.4
Native Hawaiian/other Pacific Islander 74 59 79.7 15 20.3 61 47 77.0 14 23.0
White 8,580 7,048 82.1 1,532 17.9 6,409 5,310 82.9 1,099 17.1
Multiracial 967 791 81.8 176 18.2 530 435 82.1 95 17.9
Transmission categorye
Male-to-male sexual contactf 22,659 18,717 82.6 3,942 17.4 17,730 14,833 83.7 2,898 16.3
Injection drug useg 2,326 1,757 75.5 569 24.5 1,715 1,327 77.4 388 22.6
Male 1,311 975 74.3 337 25.7 928 710 76.6 217 23.4
Female 1,015 783 77.1 232 22.9 787 617 78.4 170 21.6
Male-to-male sexual contactf and injection drug useg 1,301 1,026 78.8 276 21.2 866 705 81.4 161 18.6
Heterosexual contacth 7,244 5,972 82.4 1,272 17.6 5,491 4,505 82.0 986 18.0
Male 2,178 1,779 81.7 399 18.3 1,588 1,298 81.7 290 18.3
Female 5,065 4,192 82.8 873 17.2 3,903 3,207 82.2 696 17.8
Totali 33,606 27,535 81.9 6,071 18.1 25,879 21,435 82.8 4,444 17.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Hispanic/Latino persons can be of any race
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

2021 2022 (January-September, preliminary)a
Total diagnoses ≥ 1 CD4 or VL tests No CD4 or VL test Total diagnoses ≥ 1 CD4 or VL tests No CD4 or VL test
Area of residence No. No. % No. % No. No. % No. %
Alabama 625 502 80.3 123 19.7 359 296 82.5 63 17.5
Alaska 30 28 93.3 2 6.7 19 18 94.7 1 5.3
Arizona 781 661 84.6 120 15.4 671 568 84.6 103 15.4
Arkansas 338 261 77.2 77 22.8 243 194 79.8 49 20.2
California 4,399 3,628 82.5 771 17.5 3,214 2,667 83.0 547 17.0
Colorado 406 343 84.5 63 15.5 325 268 82.5 57 17.5
Connecticut 233 204 87.6 29 12.4 169 143 84.6 26 15.4
Delaware 81 68 84.0 13 16.0 92 78 84.8 14 15.2
District of Columbia 195 154 79.0 41 21.0 171 146 85.4 25 14.6
Florida 4,072 3,366 82.7 706 17.3 3,732 3,147 84.3 585 15.7
Georgia 2,371 1,934 81.6 437 18.4 1,946 1,632 83.9 314 16.1
Hawaii 65 55 84.6 10 15.4 38 32 84.2 6 15.8
Illinois 1,195 1,022 85.5 173 14.5 872 752 86.2 120 13.8
Indiana 528 401 75.9 127 24.1 455 350 76.9 105 23.1
Iowa 124 106 85.5 18 14.5 79 72 91.1 7 8.9
Kansas 154 139 90.3 15 9.7 99 92 92.9 7 7.1
Kentucky 390 289 74.1 101 25.9 300 238 79.3 62 20.7
Louisiana 899 725 80.6 174 19.4 674 529 78.5 145 21.5
Maine 31 27 87.1 4 12.9 28 27 96.4 1 3.6
Maryland 749 650 86.8 99 13.2 566 511 90.3 55 9.7
Massachusetts 440 403 91.6 37 8.4 248 220 88.7 28 11.3
Michigan 633 547 86.4 86 13.6 474 413 87.1 61 12.9
Minnesota 297 254 85.5 43 14.5 193 160 82.9 33 17.1
Mississippi 419 299 71.4 120 28.6 293 160 54.6 133 45.4
Missouri 549 427 77.8 122 22.2 391 321 82.1 70 17.9
Montana 22 21 95.5 1 4.5 10 7 70.0 3 30.0
Nebraska 105 88 83.8 17 16.2 71 62 87.3 9 12.7
Nevada 501 439 87.6 62 12.4 405 366 90.4 39 9.6
New Hampshire 32 32 100 0 0.0 24 17 70.8 7 29.2
New Mexico 149 127 85.2 22 14.8 67 60 89.6 7 10.4
New York 2,116 1,814 85.7 302 14.3 1,628 1,423 87.4 205 12.6
North Carolina 1,390 1,115 80.2 275 19.8 1,047 849 81.1 198 18.9
North Dakota 37 31 83.8 6 16.2 5 3 60.0 2 40.0
Ohio 909 757 83.3 152 16.7 668 560 83.8 108 16.2
Oklahoma 387 303 78.3 84 21.7 223 175 78.5 48 21.5
Oregon 202 159 78.7 43 21.3 191 163 85.3 28 14.7
Rhode Island 68 58 85.3 10 14.7 44 42 95.5 2 4.5
South Carolina 652 557 85.4 95 14.6 531 434 81.7 97 18.3
South Dakota 31 25 80.6 6 19.4 29 19 65.5 10 34.5
Tennessee 831 583 70.2 248 29.8 656 473 72.1 183 27.9
Texas 4,363 3,431 78.6 932 21.4 3,142 2,519 80.2 623 19.8
Utah 133 111 83.5 22 16.5 110 89 80.9 21 19.1
Vermont 12 12 100 0 0.0 4 3 75.0 1 25.0
Virginia 792 633 79.9 159 20.1 642 523 81.5 119 18.5
Washington 461 407 88.3 54 11.7 393 343 87.3 50 12.7
West Virginia 149 107 71.8 42 28.2 118 72 61.0 46 39.0
Wisconsin 253 226 89.3 27 10.7 211 191 90.5 20 9.5
Wyoming 7 6 85.7 1 14.3 9 8 88.9 1 11.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

2021 2022 (January-September, preliminary)a
Total diagnoses ≥ 1 CD4 or VL tests No CD4 or VL test Total diagnoses ≥ 1 CD4 or VL tests No CD4 or VL test
Area of residence No. No. % No. % No. No. % No. %
Arizona
Maricopa County 518 446 86.1 72 13.9 447 387 86.6 60 13.4
California
Alameda County 185 162 87.6 23 12.4 151 130 86.1 21 13.9
Los Angeles County 1,486 1,194 80.3 292 19.7 995 817 82.1 178 17.9
Orange County 266 230 86.5 36 13.5 184 154 83.7 30 16.3
Riverside County 258 199 77.1 59 22.9 221 178 80.5 43 19.5
Sacramento County 175 151 86.3 24 13.7 107 96 89.7 11 10.3
San Bernardino County 301 230 76.4 71 23.6 204 147 72.1 57 27.9
San Diego County 369 307 83.2 62 16.8 172 140 81.4 32 18.6
San Francisco County 185 174 94.1 11 5.9 163 148 90.8 15 9.2
District of Columbia 195 154 79.0 41 21.0 171 146 85.4 25 14.6
Florida
Broward County 570 467 81.9 103 18.1 492 418 85.0 74 15.0
Duval County 280 222 79.3 58 20.7 220 164 74.5 56 25.5
Hillsborough County 294 234 79.6 60 20.4 244 206 84.4 38 15.6
Miami-Dade County 937 768 82.0 169 18.0 927 778 83.9 149 16.1
Orange County 416 340 81.7 76 18.3 372 303 81.5 69 18.5
Palm Beach County 273 231 84.6 42 15.4 269 243 90.3 26 9.7
Pinellas County 122 99 81.1 23 18.9 97 81 83.5 16 16.5
Georgia
Cobb County 152 131 86.2 21 13.8 130 111 85.4 19 14.6
DeKalb County 342 283 82.7 59 17.3 296 245 82.8 51 17.2
Fulton County 525 438 83.4 87 16.6 463 394 85.1 69 14.9
Gwinnett County 165 144 87.3 21 12.7 127 114 89.8 13 10.2
Illinois
Cook County 843 730 86.6 113 13.4 572 497 86.9 75 13.1
Indiana
Marion County 216 170 78.7 46 21.3 187 141 75.4 46 24.6
Louisiana
East Baton Rouge Parish 141 112 79.4 29 20.6 91 75 82.4 16 17.6
Orleans Parish 145 131 90.3 14 9.7 100 86 86.0 14 14.0
Maryland
Baltimore City 156 133 85.3 23 14.7 116 107 92.2 9 7.8
Montgomery County 96 85 88.5 11 11.5 84 76 90.5 8 9.5
Prince George’s County 229 198 86.5 31 13.5 185 168 90.8 17 9.2
Massachusetts
Suffolk County 132 127 96.2 5 3.8 68 61 89.7 7 10.3
Michigan
Wayne County 256 216 84.4 40 15.6 191 161 84.3 30 15.7
Nevada
Clark County 445 387 87.0 58 13.0 369 333 90.2 36 9.8
New York
Bronx County 416 359 86.3 57 13.7 296 250 84.5 46 15.5
Kings County 441 378 85.7 63 14.3 345 312 90.4 33 9.6
New York County 317 262 82.6 55 17.4 252 210 83.3 42 16.7
Queens County 333 285 85.6 48 14.4 260 233 89.6 27 10.4
North Carolina
Mecklenburg County 278 226 81.3 52 18.7 214 167 78.0 47 22.0
Ohio
Cuyahoga County 164 146 89.0 18 11.0 100 86 86.0 14 14.0
Franklin County 187 161 86.1 26 13.9 144 125 86.8 19 13.2
Hamilton County 122 109 89.3 13 10.7 74 66 89.2 8 10.8
Pennsylvania
Philadelphia County 360 301 83.6 59 16.4 248 204 82.3 44 17.7
Tennessee
Shelby County 294 177 60.2 117 39.8 268 172 64.2 96 35.8
Texas
Bexar County 328 263 80.2 65 19.8 254 205 80.7 49 19.3
Dallas County 798 613 76.8 185 23.2 660 516 78.2 144 21.8
Harris County 1,161 873 75.2 288 24.8 954 757 79.4 197 20.6
Tarrant County 302 236 78.1 66 21.9 250 181 72.4 69 27.6
Travis County 225 195 86.7 30 13.3 174 152 87.4 22 12.6
Washington
King County 218 194 89.0 24 11.0 212 187 88.2 25 11.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

Persons alive at year-end 2021 VL < 200 copies/mL
No. No. %
Gender
Male 733,871 486,719 66.3
Female 217,656 140,231 64.4
Transgender womana 11,674 7,757 66.4
Transgender mana 499 370 74.1
Additional gender identityb 302 223 73.8
Age at year-end 2020 (yr)
13–24 27,140 17,677 65.1
25–34 152,935 97,532 63.8
35–44 183,689 117,369 63.9
45–54 233,009 154,813 66.4
≥ 55 367,229 247,909 67.5
Race/ethnicity
American Indian/Alaska Native 2,992 1,908 63.8
Asianc 15,188 10,614 69.9
Black/African American 386,688 238,353 61.6
Hispanic/Latinod 227,387 146,163 64.3
Native Hawaiian/other Pacific Islander 855 542 63.4
White 280,199 200,892 71.7
Multiracial 50,067 36,786 73.5
Transmission categorye
Male-to-male sexual contactf 561,493 385,253 68.6
Injection drug useg 96,246 53,923 56.0
Male 54,849 28,778 52.5
Female 41,397 25,145 60.7
Male-to-male sexual contactf and injection drug useg 53,043 34,514 65.1
Heterosexual contacth 239,228 153,516 64.2
Male 69,386 42,133 60.7
Female 169,842 111,383 65.6
Otheri 13,992 8,094 57.8
Male 7,039 3,996 56.8
Female 6,953 4,098 58.9
Totalj 964,002 635,300 65.9

Abbreviations: VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Includes Asian/Pacific Islander legacy cases.
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
j Includes 626 persons of unknown race/ethnicity.

Persons alive at year-end 2021 VL < 200 copies/mL
No. No. %
Alabama 13,774 8,146 59.1
Alaska 718 572 79.7
Arizona 17,490 10,955 62.6
Arkansas 5,900 3,097 52.5
California 131,709 87,675 66.6
Colorado 13,022 7,890 60.6
Connecticut 10,406 7,484 71.9
Delaware 3,439 2,525 73.4
District of Columbia 13,401 7,418 55.4
Florida 113,218 77,793 68.7
Georgia 57,083 35,470 62.1
Hawaii 2,323 1,839 79.2
Illinois 34,556 21,881 63.3
Indiana 11,821 8,322 70.4
Iowa 2,923 2,389 81.7
Kansas 3,340 2,523 75.5
Kentucky 7,759 5,062 65.2
Louisiana 20,700 14,263 68.9
Maine 1,650 1,279 77.5
Maryland 32,719 20,214 61.8
Massachusetts 20,672 14,483 70.1
Michigan 16,652 11,987 72.0
Minnesota 8,915 5,962 66.9
Mississippia 9,474 5,646 59.6
Missouri 12,570 8,403 66.8
Montana 698 564 80.8
Nebraska 2,274 1,541 67.8
Nevada 10,921 6,971 63.8
New Hampshire 1,333 1,006 75.5
New Mexico 3,873 2,183 56.4
New York 122,351 79,119 64.7
North Carolina 32,933 22,383 68.0
North Dakota 506 317 62.6
Ohio 23,181 15,307 66.0
Oklahoma 6,585 4,046 61.4
Oregon 7,268 5,616 77.3
Rhode Island 2,647 1,809 68.3
South Carolina 17,474 12,679 72.6
South Dakota 687 380 55.3
Tennessee 17,938 12,005 66.9
Texas 96,292 60,494 62.8
Utah 3,317 2,338 70.5
Vermont 712 531 74.6
Virginia 23,635 15,378 65.1
Washington 14,141 11,121 78.6
West Virginia 2,056 1,118 54.4
Wisconsin 6,579 4,869 74.0
Wyoming 367 247 67.3
Total 964,002 635,300 65.9

Abbreviations: VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

Persons alive at year-end 2021 VL < 200 copies/mL
Area of residence No. No. %
Arizona
Maricopa County 11,910 7,494 62.9
California
Alameda County 5,808 4,152 71.5
Los Angeles County 49,007 31,877 65.0
Orange County 6,963 4,557 65.4
Riverside County 9,862 7,691 78.0
Sacramento County 4,467 3,128 70.0
San Bernardino County 4,769 2,919 61.2
San Diego County 13,163 7,748 58.9
San Francisco County 11,437 8,350 73.0
District of Columbia 13,401 7,418 55.4
Florida
Broward County 19,788 13,586 68.7
Duval County 6,218 4,324 69.5
Hillsborough County 7,162 5,196 72.5
Miami-Dade County 26,224 16,142 61.6
Orange County 8,938 6,433 72.0
Palm Beach County 7,887 5,100 64.7
Pinellas County 4,812 3,745 77.8
Georgia
Cobb County 3,501 2,332 66.6
DeKalb County 8,802 5,637 64.0
Fulton County 15,851 9,885 62.4
Gwinnett County 3,199 2,147 67.1
Illinois
Cook County 24,919 15,173 60.9
Indiana
Marion County 4,752 3,507 73.8
Louisiana
East Baton Rouge Parish 3,983 3,021 75.8
Orleans Parish 4,721 3,199 67.8
Maryland
Baltimore City 10,110 6,303 62.3
Montgomery County 3,850 2,028 52.7
Prince George’s County 7,865 4,763 60.6
Massachusetts
Suffolk County 5,527 3,765 68.1
Michigan
Wayne County 6,974 4,767 68.4
Nevada
Clark County 9,255 5,909 63.8
New York
Bronx County 26,854 17,245 64.2
Kings County 25,601 16,330 63.8
New York County 25,777 15,598 60.5
Queens County 15,810 10,089 63.8
North Carolina
Mecklenburg County 6,013 4,025 66.9
Ohio
Cuyahoga County 4,810 3,132 65.1
Franklin County 5,072 3,581 70.6
Hamilton County 3,037 1,954 64.3
Pennsylvania
Philadelphia County 16,404 10,051 61.3
Tennessee
Shelby County 6,278 4,007 63.8
Texas
Bexar County 6,596 4,112 62.3
Dallas County 18,809 11,348 60.3
Harris County 26,727 17,120 64.1
Tarrant County 6,120 4,162 68.0
Travis County 5,032 3,506 69.7
Washington
King County 6,965 5,707 81.9

Abbreviations: VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].

Note. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

2017 2018 2019
Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec
No. No. % No. No. % No. No. %
Sex at birth
Male 143,672 993,840 14.5 204,039 989,200 20.6 253,750 989,200 25.7
Female 11,261 227,240 5.0 15,796 227,010 7.0 21,040 227,010 9.3
Age (yr)
16–24 20,080 259,130 7.7 29,300 246,290 11.9 37,595 246,290 15.3
25–34 62,346 425,690 14.6 90,658 434,680 20.9 111,654 434,680 25.7
35–44 36,475 233,560 15.6 50,699 238,470 21.3 64,030 238,470 26.9
45–54 23,763 180,870 13.1 31,487 173,420 18.2 37,396 173,420 21.6
≥ 55 12,308 121,830 10.1 17,715 123,350 14.4 24,159 123,350 19.6
Race/ethnicityd
Black/African American 19,776 475,100 4.2 29,059 468,540 6.2 37,447 468,540 8.0
Hispanic/Latinoe 23,416 299,580 7.8 35,110 312,820 11.2 45,212 312,820 14.5
Other 7,020 132,040 5.3 9,890 131,180 7.5 12,289 131,180 9.4
White 104,820 311,250 33.7 145,894 300,650 48.5 179,985 300,650 59.9
Total 155,032 1,221,080 12.7 219,954 1,216,210 18.1 274,933 1,216,210 22.6
2020 (COVID-19 pandemic) 2021 2022 (January – September)
Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec
No. No. % No. No. % No. No. %
Sex at birth
Male 276,915 989,200 28.0 337,697 989,200 34.1 355,379 989,200 35.9
Female 23,562 227,010 10.4 28,014 227,010 12.3 26,888 227,010 11.8
Age (yr)
16–24 37,709 246,290 15.3 48,552 246,290 19.7 46,933 246,290 19.1
25–34 120,220 434,680 27.7 145,758 434,680 33.5 151,005 434,680 34.7
35–44 71,840 238,470 30.1 88,516 238,470 37.1 96,302 238,470 40.4
45–54 40,454 173,420 23.3 46,224 173,420 26.7 47,616 173,420 27.5
≥ 55 30,208 123,350 24.5 36,740 123,350 29.8 40,283 123,350 32.7
Race/ethnicityd
Black/African American 43,332 468,540 9.2 51,878 468,540 11.1 51,708 468,540 11.0
Hispanic/Latinoe 51,104 312,820 16.3 64,018 312,820 20.5 66,177 312,820 21.2
Other 12,840 131,180 9.8 15,779 131,180 12.0 16,779 131,180 12.8
White 193,268 300,650 64.3 234,318 300,650 77.9 247,701 300,650 82.4
Total 300,544 1,216,210 24.7 365,994 1,216,210 30.1 382,364 1,216,210 31.4

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

a Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.
b Estimated by using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018–2022 PrEP coverage data.
c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
d Race/ethnicity data were only available for <40% of persons prescribed PrEP each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.
e Hispanic/Latino persons can be of any race.

2017 2018 2019
Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec
No. No. % No. No. % No. No. %
Alabama 1,010 11,390 8.9 1,531 11,020 13.9 1,834 11,020 16.6
Alaska 125 2,370 5.3 199 1,780 11.2 227 1,780 12.8
Arizona 2,250 26,820 8.4 3,494 25,780 13.6 4,575 25,780 17.7
Arkansas 412 4,840 8.5 585 5,130 11.4 728 5,130 14.2
California 26,071 166,150 15.7 35,902 165,030 21.8 41,579 165,030 25.2
Colorado 2,410 25,510 9.4 3,449 25,120 13.7 4,396 25,120 17.5
Connecticut 1,574 10,970 14.3 2,268 9,560 23.7 2,661 9,560 27.8
Delaware 280 4,860 5.8 423 4,400 9.6 476 4,400 10.8
District of Columbia 3,800 13,710 27.7 5,007 12,950 38.7 5,882 12,950 45.4
Florida 8,493 125,160 6.8 14,715 125,330 11.7 21,744 125,330 17.3
Georgia 4,462 40,680 11.0 6,295 39,030 16.1 8,645 39,030 22.1
Hawaii 438 5,440 8.1 679 4,360 15.6 815 4,360 18.7
Idaho 265 3,860 6.9 370 4,790 7.7 479 4,790 10.0
Illinois 10,133 54,620 18.6 13,858 55,860 24.8 16,641 55,860 29.8
Indiana 1,553 21,640 7.2 2,195 22,170 9.9 2,979 22,170 13.4
Iowa 764 4,280 17.9 1,145 4,760 24.1 1,414 4,760 29.7
Kansas 523 5,570 9.4 722 5,060 14.3 902 5,060 17.8
Kentucky 750 13,170 5.7 1,205 12,990 9.3 1,600 12,990 12.3
Louisiana 2,190 15,490 14.1 3,302 15,920 20.7 3,916 15,920 24.6
Maine 318 3,270 9.7 499 3,950 12.6 651 3,950 16.5
Maryland 2,677 28,150 9.5 3,944 27,300 14.4 4,929 27,300 18.1
Massachusetts 5,503 25,110 21.9 7,615 24,900 30.6 9,303 24,900 37.4
Michigan 2,254 28,520 7.9 3,471 29,570 11.7 4,349 29,570 14.7
Minnesota 2,506 23,770 10.5 3,469 21,720 16.0 4,202 21,720 19.3
Mississippi 471 5,030 9.4 653 4,530 14.4 948 4,530 20.9
Missouri 1,882 19,420 9.7 2,720 18,370 14.8 3,474 18,370 18.9
Montana 119 2,750 4.3 185 2,290 8.1 268 2,290 11.7
Nebraska 346 2,590 13.4 471 2,180 21.6 619 2,180 28.4
Nevada 1,049 10,870 9.7 1,485 11,390 13.0 2,181 11,390 19.1
New Hampshire 319 3,110 10.3 498 3,020 16.5 618 3,020 20.5
New Jersey 3,273 28,590 11.4 4,587 25,280 18.1 5,667 25,280 22.4
New Mexico 612 6,720 9.1 810 6,800 11.9 1,072 6,800 15.8
New York 22,484 74,450 30.2 30,023 72,640 41.3 35,281 72,640 48.6
North Carolina 2,584 33,110 7.8 4,019 32,490 12.4 5,397 32,490 16.6
North Dakota 108 1,230 8.8 160 1,520 10.5 187 1,520 12.3
Ohio 3,470 40,940 8.5 4,735 40,320 11.7 6,095 40,320 15.1
Oklahoma 529 11,030 4.8 810 11,030 7.3 1,155 11,030 10.5
Oregon 2,048 20,720 9.9 2,763 19,750 14.0 3,400 19,750 17.2
Pennsylvania 6,085 36,160 16.8 8,502 36,490 23.3 10,092 36,490 27.7
Puerto Ricod 123 9,700 1.3 246 9,700 2.5 329 9,700 3.4
Rhode Island 625 4,360 14.3 862 3,880 22.2 1,082 3,880 27.9
South Carolina 703 10,390 6.8 1,241 10,390 11.9 1,724 10,390 16.6
South Dakota 55 1,000 5.5 101 910 11.1 150 910 16.5
Tennessee 1,709 22,890 7.5 2,596 22,460 11.6 3,892 22,460 17.3
Texas 11,084 123,400 9.0 17,702 123,790 14.3 23,120 123,790 18.7
Utah 1,050 6,900 15.2 1,490 6,840 21.8 2,035 6,840 29.8
Vermont 217 1,490 14.6 280 1,060 26.4 337 1,060 31.8
Virginia 2,043 33,670 6.1 3,121 31,430 9.9 4,403 31,430 14.0
Washington 6,332 35,600 17.8 8,238 40,050 20.6 9,885 40,050 24.7
West Virginia 237 3,660 6.5 369 5,250 7.0 570 5,250 10.9
Wisconsin 1,289 14,230 9.1 1,856 12,980 14.3 2,471 12,980 19.0
Wyoming 49 1,410 3.5 73 890 8.2 96 890 10.8
2020 (COVID-19 pandemic) 2021 2022 (January – September)
Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec
No. No. % No. No. % No. No. %
Alabama 1,908 11,020 17.3 2,764 11,020 25.1 3,018 11,020 27.4
Alaska 243 1,780 13.7 308 1,780 17.3 347 1,780 19.5
Arizona 5,055 25,780 19.6 6,571 25,780 25.5 7,297 25,780 28.3
Arkansas 861 5,130 16.8 1,275 5,130 24.9 1,449 5,130 28.2
California 42,234 165,030 25.6 50,239 165,030 30.4 53,925 165,030 32.7
Colorado 4,791 25,120 19.1 6,187 25,120 24.6 6,625 25,120 26.4
Connecticut 2,459 9,560 25.7 3,036 9,560 31.8 3,473 9,560 36.3
Delaware 474 4,400 10.8 645 4,400 14.7 733 4,400 16.7
District of Columbia 5,967 12,950 46.1 6,790 12,950 52.4 6,945 12,950 53.6
Florida 34,501 125,330 27.5 42,584 125,330 34.0 39,596 125,330 31.6
Georgia 9,754 39,030 25.0 12,173 39,030 31.2 12,271 39,030 31.4
Hawaii 902 4,360 20.7 1,134 4,360 26.0 1,308 4,360 30.0
Idaho 666 4,790 13.9 878 4,790 18.3 933 4,790 19.5
Illinois 15,962 55,860 28.6 18,417 55,860 33.0 19,543 55,860 35.0
Indiana 3,195 22,170 14.4 4,261 22,170 19.2 4,801 22,170 21.7
Iowa 1,555 4,760 32.7 1,951 4,760 41.0 1,945 4,760 40.9
Kansas 951 5,060 18.8 1,278 5,060 25.3 1,383 5,060 27.3
Kentucky 1,654 12,990 12.7 2,225 12,990 17.1 2,576 12,990 19.8
Louisiana 3,566 15,920 22.4 4,152 15,920 26.1 4,156 15,920 26.1
Maine 669 3,950 16.9 908 3,950 23.0 977 3,950 24.7
Maryland 4,797 27,300 17.6 5,793 27,300 21.2 5,981 27,300 21.9
Massachusetts 9,369 24,900 37.6 10,164 24,900 40.8 11,348 24,900 45.6
Michigan 4,665 29,570 15.8 5,900 29,570 20.0 6,261 29,570 21.2
Minnesota 4,206 21,720 19.4 5,251 21,720 24.2 5,817 21,720 26.8
Mississippi 1,091 4,530 24.1 1,592 4,530 35.1 1,525 4,530 33.7
Missouri 3,564 18,370 19.4 4,173 18,370 22.7 4,484 18,370 24.4
Montana 294 2,290 12.8 395 2,290 17.2 457 2,290 20.0
Nebraska 718 2,180 32.9 1,004 2,180 46.1 1,128 2,180 51.7
Nevada 2,497 11,390 21.9 4,877 11,390 42.8 4,422 11,390 38.8
New Hampshire 650 3,020 21.5 803 3,020 26.6 886 3,020 29.3
New Jersey 5,904 25,280 23.4 7,267 25,280 28.7 7,725 25,280 30.6
New Mexico 1,235 6,800 18.2 1,594 6,800 23.4 1,767 6,800 26.0
New York 34,116 72,640 47.0 39,082 72,640 53.8 40,223 72,640 55.4
North Carolina 6,161 32,490 19.0 7,964 32,490 24.5 8,697 32,490 26.8
North Dakota 183 1,520 12.0 246 1,520 16.2 295 1,520 19.4
Ohio 6,802 40,320 16.9 8,465 40,320 21.0 9,071 40,320 22.5
Oklahoma 1,523 11,030 13.8 2,321 11,030 21.0 2,423 11,030 22.0
Oregon 3,826 19,750 19.4 4,691 19,750 23.8 5,283 19,750 26.7
Pennsylvania 10,562 36,490 28.9 13,049 36,490 35.8 14,090 36,490 38.6
Puerto Ricod 368 9,700 3.8 608 9,700 6.3 698 9,700 7.2
Rhode Island 1,155 3,880 29.8 1,512 3,880 39.0 1,616 3,880 41.6
South Carolina 2,103 10,390 20.2 2,934 10,390 28.2 3,185 10,390 30.7
South Dakota 141 910 15.5 214 910 23.5 263 910 28.9
Tennessee 5,166 22,460 23.0 7,227 22,460 32.2 7,877 22,460 35.1
Texas 27,496 123,790 22.2 34,728 123,790 28.1 35,883 123,790 29.0
Utah 2,366 6,840 34.6 3,262 6,840 47.7 3,535 6,840 51.7
Vermont 321 1,060 30.3 480 1,060 45.3 501 1,060 47.3
Virginia 5,117 31,430 16.3 6,280 31,430 20.0 6,607 31,430 21.0
Washington 10,065 40,050 25.1 11,377 40,050 28.4 12,134 40,050 30.3
West Virginia 521 5,250 9.9 707 5,250 13.5 785 5,250 15.0
Wisconsin 2,529 12,980 19.5 2,816 12,980 21.7 2,928 12,980 22.6
Wyoming 98 890 11.0 139 890 15.6 160 890 18.0

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

a Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
b Estimated by using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018–2022 PrEP coverage data.
c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
d Number of persons with PrEP indications in Puerto Rico is not available in 2017. Number of persons with PrEP indications in 2018 is used for 2017 denominator.

2017 2018 2019
Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec
No. No. % No. No. % No. No. %
Arizona
Maricopa County 1,787 23,540 7.6 2,792 22,720 12.3 3,532 22,720 15.5
California
Alameda County 1,401 7,260 19.3 1,851 8,930 20.7 2,156 8,930 24.1
Los Angeles County 8,656 64,180 13.5 12,077 67,450 17.9 13,679 67,450 20.3
Orange County 1,050 9,990 10.5 1,602 10,510 15.2 2,036 10,510 19.4
Riverside County 993 11,040 9.0 1,419 11,080 12.8 1,797 11,080 16.2
Sacramento County 581 5,460 10.6 787 5,920 13.3 955 5,920 16.1
San Bernardino County 379 12,450 3.0 608 11,890 5.1 751 11,890 6.3
San Diego County 2,340 19,420 12.0 3,360 14,500 23.2 3,729 14,500 25.7
San Francisco County 6,245 11,330 55.1 7,811 10,840 72.1 8,828 10,840 81.4
District of Columbia 3,800 13,710 27.7 5,007 12,950 38.7 5,882 12,950 45.4
Florida
Broward County 1,975 20,030 9.9 2,906 20,470 14.2 3,837 20,470 18.7
Duval County 243 9,250 2.6 367 8,970 4.1 496 8,970 5.5
Hillsborough County 613 12,670 4.8 1,094 12,910 8.5 1,385 12,910 10.7
Miami-Dade County 1,936 22,190 8.7 3,796 21,760 17.4 6,462 21,760 29.7
Orange County 1,011 16,500 6.1 1,870 15,310 12.2 2,782 15,310 18.2
Palm Beach County 366 7,620 4.8 577 9,170 6.3 883 9,170 9.6
Pinellas County 481 10,470 4.6 820 9,530 8.6 1,139 9,530 12.0
Georgia
Cobb County 272 3,570 7.6 388 3,070 12.6 569 3,070 18.5
DeKalb County 863 6,370 13.5 1,170 6,290 18.6 1,539 6,290 24.5
Fulton County 1,884 12,060 15.6 2,553 13,120 19.5 3,298 13,120 25.1
Gwinnett County 318 3,390 9.4 458 3,240 14.1 686 3,240 21.2
Illinois
Cook County 8,490 38,270 22.2 11,420 39,060 29.2 13,619 39,060 34.9
Indiana
Marion County 688 8,490 8.1 867 9,150 9.5 1,149 9,150 12.6
Louisiana
East Baton Rouge Parish 223 1,290 17.3 437 1,810 24.1 489 1,810 27.0
Orleans Parish 860 5,230 16.4 1,193 4,590 26.0 1,512 4,590 32.9
Maryland
Baltimore City 466 6,000 7.8 655 6,330 10.3 900 6,330 14.2
Montgomery County 513 5,790 8.9 765 5,770 13.3 894 5,770 15.5
Prince George’s County 439 3,830 11.5 653 4,040 16.2 799 4,040 19.8
Massachusetts
Suffolk County 1,673 7,050 23.7 2,219 6,520 34.0 2762 6,520 42.4
Michigan
Wayne County 686 9,470 7.2 1,020 9,270 11.0 1,201 9,270 13.0
Nevada
Clark County 889 8,790 10.1 1,244 11,670 10.7 1,860 11,670 15.9
New Jersey
Essex County 393 5,190 7.6 576 4,090 14.1 679 4,090 16.6
Hudson County 629 4,720 13.3 859 4,650 18.5 1,057 4,650 22.7
New York
Bronx County 1,290 6,690 19.3 1,984 5,570 35.6 2,194 5,570 39.4
Kings County 4,745 15,300 31.0 6,324 15,650 40.4 7,574 15,650 48.4
New York County 9,453 14,790 63.9 12,162 15,540 78.3 14,147 15,540 91.0
Queens County 2,487 8,740 28.5 3,272 9,230 35.4 3,857 9,230 41.8
North Carolina
Mecklenburg County 654 9,430 6.9 965 8,450 11.4 1,343 8,450 15.9
Ohio
Cuyahoga County 596 8,200 7.3 811 7,520 10.8 953 7,520 12.7
Franklin County 1,286 13,660 9.4 1,616 11,620 13.9 2,032 11,620 17.5
Hamilton County 259 6,430 4.0 434 7,720 5.6 564 7,720 7.3
Pennsylvania
Philadelphia County 2,356 8,550 27.6 3,221 9,840 32.7 3,650 9,840 37.1
Puerto Rico
San Juan Municipiod 16 2,190 0.7 21 2,190 1.0 25 2,190 1.1
Tennessee
Shelby County 301 7,590 4.0 460 6,450 7.1 633 6,450 9.8
Texas
Bexar County 665 13,010 5.1 1,142 11,920 9.6 1,530 11,920 12.8
Dallas County 2,119 22,000 9.6 3,230 28,670 11.3 4,095 28,670 14.3
Harris County 2,520 39,780 6.3 3,937 40,670 9.7 4,929 40,670 12.1
Tarrant County 658 11,550 5.7 1,170 11,340 10.3 1,452 11,340 12.8
Travis County 2,176 10,810 20.1 3,346 11,590 28.9 4,527 11,590 39.1
Washington
King County 4,557 13,690 33.3 5,769 17,890 32.2 6,890 17,890 38.5
2020 (COVID-19 pandemic) 2021 2022 (January – September)
Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec Persons prescribed PrEPa Persons with PrEP indicationsb PrEP coveragec
No. No. % No. No. % No. No. %
Arizona
Maricopa County 3,891 22,720 17.1 5,026 22,720 22.1 5,618 22,720 24.7
California
Alameda County 2,013 8,930 22.5 2,217 8,930 24.8 2,389 8,930 26.8
Los Angeles County 14,705 67,450 21.8 18,457 67,450 27.4 20,495 67,450 30.4
Orange County 2,195 10,510 20.9 2,832 10,510 26.9 2,917 10,510 27.8
Riverside County 1,933 11,080 17.4 2,538 11,080 22.9 2,809 11,080 25.4
Sacramento County 976 5,920 16.5 1,103 5,920 18.6 1,197 5,920 20.2
San Bernardino County 816 11,890 6.9 1,190 11,890 10.0 1,340 11,890 11.3
San Diego County 3,795 14,500 26.2 4,430 14,500 30.6 4,707 14,500 32.5
San Francisco County 8,133 10,840 75.0 8,189 10,840 75.5 8,116 10,840 74.9
District of Columbia 5,967 12,950 46.1 6,790 12,950 52.4 6,945 12,950 53.6
Florida
Broward County 6,779 20,470 33.1 8,328 20,470 40.7 7,070 20,470 34.5
Duval County 720 8,970 8.0 883 8,970 9.8 1,188 8,970 13.2
Hillsborough County 1,534 12,910 11.9 2,043 12,910 15.8 2,284 12,910 17.7
Miami-Dade County 10,190 21,760 46.8 11,410 21,760 52.4 9,361 21,760 43.0
Orange County 3,879 15,310 25.3 4,722 15,310 30.8 5,008 15,310 32.7
Palm Beach County 3,008 9,170 32.8 2,760 9,170 30.1 2,073 9,170 22.6
Pinellas County 1,225 9,530 12.9 1,655 9,530 17.4 1,876 9,530 19.7
Georgia
Cobb County 656 3,070 21.4 812 3,070 26.4 825 3,070 26.9
DeKalb County 1,680 6,290 26.7 2,016 6,290 32.1 2,012 6,290 32.0
Fulton County 3,590 13,120 27.4 4,269 13,120 32.5 4,235 13,120 32.3
Gwinnett County 797 3,240 24.6 1,005 3,240 31.0 1,027 3,240 31.7
Illinois
Cook County 12,891 39,060 33.0 14,755 39,060 37.8 15,455 39,060 39.6
Indiana
Marion County 1,209 9,150 13.2 1,591 9,150 17.4 1,788 9,150 19.5
Louisiana
East Baton Rouge Parish 529 1,810 29.2 584 1,810 32.3 536 1,810 29.6
Orleans Parish 1,328 4,590 28.9 1,517 4,590 33.1 1,486 4,590 32.4
Maryland
Baltimore City 841 6,330 13.3 974 6,330 15.4 984 6,330 15.5
Montgomery County 898 5,770 15.6 1,151 5,770 19.9 1,258 5,770 21.8
Prince George’s County 819 4,040 20.3 984 4,040 24.4 949 4,040 23.5
Massachusetts
Suffolk County 2,798 6,520 42.9 2,809 6,520 43.1 3,136 6,520 48.1
Michigan
Wayne County 1,230 9,270 13.3 1,554 9,270 16.8 1,613 9,270 17.4
Nevada
Clark County 2,094 11,670 17.9 4,284 11,670 36.7 3,491 11,670 29.9
New Jersey
Essex County 710 4,090 17.4 836 4,090 20.4 869 4,090 21.2
Hudson County 1,065 4,650 22.9 1,301 4,650 28.0 1,384 4,650 29.8
New York
Bronx County 2,011 5,570 36.1 2,074 5,570 37.2 1,853 5,570 33.3
Kings County 7,432 15,650 47.5 8,871 15,650 56.7 9,080 15,650 58.0
New York County 13,748 15,540 88.5 15,745 15,540 101.3 16,059 15,540 103.3
Queens County 3,795 9,230 41.1 4,279 9,230 46.4 4,514 9,230 48.9
North Carolina
Mecklenburg County 1,575 8,450 18.6 1,974 8,450 23.4 2,069 8,450 24.5
Ohio
Cuyahoga County 963 7,520 12.8 1,261 7,520 16.8 1,445 7,520 19.2
Franklin County 2,301 11,620 19.8 2,731 11,620 23.5 2,793 11,620 24.0
Hamilton County 638 7,720 8.3 815 7,720 10.6 862 7,720 11.2
Pennsylvania
Philadelphia County 3,500 9,840 35.6 4,049 9,840 41.1 4,345 9,840 44.2
Puerto Rico
San Juan Municipiod 27 2,190 1.2 62 2,190 2.8 99 2,190 4.5
Tennessee
Shelby County 812 6,450 12.6 941 6,450 14.6 1,002 6,450 15.5
Texas
Bexar County 1,783 11,920 15.0 2,355 11,920 19.8 2,508 11,920 21.0
Dallas County 5,152 28,670 18.0 6,544 28,670 22.8 6,432 28,670 22.4
Harris County 5,977 40,670 14.7 7,479 40,670 18.4 7,679 40,670 18.9
Tarrant County 1,635 11,340 14.4 2,104 11,340 18.6 2,190 11,340 19.3
Travis County 5,043 11,590 43.5 5,784 11,590 49.9 5,914 11,590 51.0
Washington
King County 6,965 17,890 38.9 7,634 17,890 42.7 7,999 17,890 44.7

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

a Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
b Estimated by using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018–2022 PrEP coverage data.
c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
d Number of persons with PrEP indications in San Juan Municipio is not available in 2017. Number of persons with PrEP indications in 2018 is used for 2017 denominator.
e Data value <40 was not reported due to unreliability.

Jurisdictions Territories States
Arizona Puerto Ricoa Alabama
Maricopa County San Juan Municipioa Arkansas
California Kentucky
Alameda County Mississippi
Los Angeles County Missouri
Orange County Oklahoma
Riverside County South Carolina
Sacramento County
San Bernardino County
San Diego County
San Francisco County
District of Columbia
Florida
Broward County
Duval County
Hillsborough County
Miami-Dade County
Orange County
Palm Beach County
Pinellas County
Georgia
Cobb County
DeKalb County
Fulton County
Gwinnett County
Illinois
Cook County
Indiana
Marion County
Louisiana
East Baton Rouge Parish
Orleans Parish
Maryland
Baltimore City
Montgomery County
Prince George’s County
Massachusetts
Suffolk County
Michigan
Wayne County
Nevada
Clark County
New Jerseya
Essex County
Hudson County
New York
Bronx County
Kings County
New York County
Queens County
North Carolina
Mecklenburg County
Ohio
Cuyahoga County
Franklin County
Hamilton County
Pennsylvaniaa
Philadelphia County
Tennessee
Shelby County
Texas
Bexar County
Dallas County
Harris County
Tarrant County
Travis County
Washington
King County

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview.

a Linkage to care and viral suppression data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Indicator 2017a 2018 2019 2020 (COVID-19 Pandemic) 2001
Reduce the estimated number of new HIV infections by 90% 37,000 36,100 34,800 33,600 32,100
Increase the percentage of people living with HIV who know their serostatus to at least 95% (knowledge of HIV status) 85.8 86.4 86.7 87.0 87.3
Reduce the number of new HIV diagnoses by 90%b 38,351 37,299 36,421 30,275 35,716
Increase the percentage of persons with newly diagnosed HIV infection linked to HIV medical care within one month of diagnosis to at least 95% 77.8 80.2 81.3 82.4 81.9
Increase the percentage of persons with diagnosed HIV infection who are virally suppressed to at least 95% 63.1 64.7 65.5 64.6 65.9
Increase the percentage of the estimated number of persons with indications for PrEP who have been classified as having been prescribed PrEP to at least 50% (PrEP coverage)c 12.7 18.1 22.6 24.7 30.1

Abbreviations: PrEP, preexposure prophylaxis; CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Information on Ending the HIV Epidemic in the U.S. can be found at https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview.

a Baseline data for EHE indicators, published at https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf. Baseline data for PrEP EHE indicator published at https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-2-no-2/index.html.
b Persons aged ≥13 years only.
c PrEP coverage, reported as a percentage, was calculated as the number of persons classified as having been been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Top of Page